<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd"><article article-type="research-article"><?OLF?><?properties olf?><front><journal-meta><journal-id journal-id-type="nlm-ta">EMBO J</journal-id><journal-title>The EMBO Journal</journal-title><issn pub-type="ppub">0261-4189</issn><issn pub-type="epub">1460-2075</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pii">7601830</article-id><article-id pub-id-type="doi">10.1038/sj.emboj.7601830</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>The CNS glycoprotein Shadoo has PrP<sup>C</sup>-like protective properties and displays reduced levels in prion infections</article-title><alt-title alt-title-type="short">Shadoo and PrP<sup>C</sup></alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Watts</surname><given-names>Joel C</given-names></name><xref ref-type="aff" rid="O1">1</xref><xref ref-type="aff" rid="O2">2</xref></contrib><contrib contrib-type="author"><name><surname>Drisaldi</surname><given-names>Bettina</given-names></name><xref ref-type="aff" rid="O1">1</xref></contrib><contrib contrib-type="author"><name><surname>Ng</surname><given-names>Vivian</given-names></name><xref ref-type="aff" rid="O1">1</xref></contrib><contrib contrib-type="author"><name><surname>Yang</surname><given-names>Jing</given-names></name><xref ref-type="aff" rid="O1">1</xref></contrib><contrib contrib-type="author"><name><surname>Strome</surname><given-names>Bob</given-names></name><xref ref-type="aff" rid="O1">1</xref></contrib><contrib contrib-type="author"><name><surname>Horne</surname><given-names>Patrick</given-names></name><xref ref-type="aff" rid="O1">1</xref></contrib><contrib contrib-type="author"><name><surname>Sy</surname><given-names>Man-Sun</given-names></name><xref ref-type="aff" rid="O3">3</xref></contrib><contrib contrib-type="author"><name><surname>Yoong</surname><given-names>Larry</given-names></name><xref ref-type="aff" rid="O1">1</xref></contrib><contrib contrib-type="author"><name><surname>Young</surname><given-names>Rebecca</given-names></name><xref ref-type="aff" rid="O4">4</xref></contrib><contrib contrib-type="author"><name><surname>Mastrangelo</surname><given-names>Peter</given-names></name><xref ref-type="aff" rid="O1">1</xref></contrib><contrib contrib-type="author"><name><surname>Bergeron</surname><given-names>Catherine</given-names></name><xref ref-type="aff" rid="O1">1</xref><xref ref-type="aff" rid="O2">2</xref></contrib><contrib contrib-type="author"><name><surname>Fraser</surname><given-names>Paul E</given-names></name><xref ref-type="aff" rid="O1">1</xref><xref ref-type="aff" rid="O5">5</xref></contrib><contrib contrib-type="author"><name><surname>Carlson</surname><given-names>George A</given-names></name><xref ref-type="aff" rid="O4">4</xref></contrib><contrib contrib-type="author"><name><surname>Mount</surname><given-names>Howard T J</given-names></name><xref ref-type="aff" rid="O1">1</xref><xref ref-type="aff" rid="O6">6</xref></contrib><contrib contrib-type="author"><name><surname>Schmitt-Ulms</surname><given-names>Gerold</given-names></name><xref ref-type="aff" rid="O1">1</xref><xref ref-type="aff" rid="O2">2</xref></contrib><contrib contrib-type="author"><name><surname>Westaway</surname><given-names>David</given-names></name><xref ref-type="aff" rid="O1">1</xref><xref ref-type="aff" rid="O2">2</xref><xref ref-type="aff" rid="O7">7</xref><xref ref-type="corresp" rid="c1">a</xref></contrib><aff id="O1"><label>1</label>Centre for Research in Neurodegenerative Diseases, University of Toronto, Toronto, Canada</aff><aff id="O2"><label>2</label>Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Canada</aff><aff id="O3"><label>3</label>Department of Pathology, School of Medicine, Case Western Reserve University, Cleveland, OH, USA</aff><aff id="O4"><label>4</label>McLaughlin Research Institute, Great Falls, MT, USA</aff><aff id="O5"><label>5</label>Department of Medical Biophysics, University of Toronto, Toronto, Canada</aff><aff id="O6"><label>6</label>Department of Medicine, University of Toronto, Toronto, Canada</aff><aff id="O7"><label>7</label>Centre for Prions and Protein Folding Diseases, University of Alberta, Alberta, Canada</aff></contrib-group><author-notes><corresp id="c1"><label>a</label>Centre for Prions and Protein Folding Diseases, University of Alberta, Room 116, Environmental Engineering Building, Edmonton, Alberta, Canada T6G 2M8. Tel.: +780 492 9377; Fax: +780 492 9352; E-mail: <email>david.westaway@ualberta.ca</email></corresp></author-notes><pub-date pub-type="epub"><day>16</day><month>08</month><year>2007</year></pub-date><fpage>1</fpage><lpage>13</lpage><history><date date-type="received"><day>6</day><month>03</month><year>2007</year></date><date date-type="accepted"><day>24</day><month>07</month><year>2007</year></date></history><copyright-statement>Copyright &#x000a9; 2007, European Molecular Biology Organization</copyright-statement><copyright-year>2007</copyright-year><permissions><license license-type="open-access" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://creativecommons.org/licenses/by-nc-nd/2.5/"><p>This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits distribution, and reproduction in any medium, provided the original author and source are credited. This license does not permit commercial exploitation or the creation of derivative works without specific permission.</p></license></permissions><abstract><p>The cellular prion protein, PrP<sup>C</sup>, is neuroprotective in a number of settings and in particular prevents cerebellar degeneration mediated by CNS-expressed Doppel or internally deleted PrP (&#x02018;&#x00394;PrP'). This paradigm has facilitated mapping of activity determinants in PrP<sup>C</sup> and implicated a cryptic PrP<sup>C</sup>-like protein, &#x02018;&#x003c0;'. Shadoo (Sho) is a hypothetical GPI-anchored protein encoded by the <italic>Sprn</italic> gene, exhibiting homology and domain organization similar to the N-terminus of PrP. Here we demonstrate <italic>Sprn</italic> expression and Sho protein in the adult CNS. Sho expression overlaps PrP<sup>C</sup>, but is low in cerebellar granular neurons (CGNs) containing PrP<sup>C</sup> and high in PrP<sup>C</sup>-deficient dendritic processes. In <italic>Prnp</italic><sup>0/0</sup> CGNs, Sho transgenes were PrP<sup>C</sup>-like in their ability to counteract neurotoxic effects of either Doppel or &#x00394;PrP. Additionally, prion-infected mice exhibit a dramatic reduction in endogenous Sho protein. Sho is a candidate for &#x003c0;, and since it engenders a PrP<sup>C</sup>-like neuroprotective activity, compromised neuroprotective activity resulting from reduced levels may exacerbate damage in prion infections. Sho may prove useful in deciphering several unresolved facets of prion biology.</p></abstract><kwd-group><kwd>neuroprotection</kwd><kwd>prions</kwd><kwd>PrP</kwd><kwd>scrapie</kwd></kwd-group><counts><page-count count="13"/></counts></article-meta></front><body><sec disp-level="1"><title>Introduction</title><p>Prions are the causative agents of neurodegenerative diseases, which include bovine spongiform encephalopathy (BSE) in cattle, scrapie in sheep, chronic wasting disease in mule deer and elk, and Creutzfeldt&#x02013;Jakob Disease (CJD) in humans. The infectious agent is believed to consist of improperly folded forms of a host-encoded protein, the cellular prion protein (PrP<sup>C</sup>). Conversion of PrP<sup>C</sup> into the disease-associated isoform, PrP<sup>Sc</sup>, is thought to be the primary pathogenic event, although the mechanisms by which PrP<sup>Sc</sup> causes disease are poorly understood. PrP<sup>C</sup> is absolutely required for disease progression, as PrP knockout (<italic>Prnp</italic><sup>0/0</sup>) mice do not succumb to disease and do not propagate infectivity following intracerebral challenge with infectious prions (<xref ref-type="bibr" rid="b8">B&#x000fc;eler <italic>et al</italic>, 1992</xref>, <xref ref-type="bibr" rid="b7">1993</xref>).</p><p>The mammalian prion protein family currently consists of two proteins: PrP<sup>C</sup> which is expressed at high levels in the central nervous system (CNS), and Doppel (Dpl), a molecule with a similar three-dimensional structure, whose postnatal expression is normally confined to the testis (<xref ref-type="bibr" rid="b53">Silverman <italic>et al</italic>, 2000</xref>; <xref ref-type="bibr" rid="b33">Mo <italic>et al</italic>, 2001</xref>). Whereas a role for Dpl in the proper functioning of the male reproductive system has been confirmed in two lines of Dpl knockout mice (<xref ref-type="bibr" rid="b2">Behrens <italic>et al</italic>, 2002</xref>; <xref ref-type="bibr" rid="b37">Paisley <italic>et al</italic>, 2004</xref>), the function of PrP<sup>C</sup>, a well-conserved neuronal glycoprotein, comprises a conundrum, in part because phenotypic alterations in <italic>Prnp</italic><sup>0/0</sup> mice have been subtle or disputed. One emerging area of consensus concerns a protective effect of PrP<sup>C</sup> against neuronal insults. In particular, PrP<sup>C</sup> is upregulated following ischemic brain damage, in both humans and mice (<xref ref-type="bibr" rid="b31">McLennan <italic>et al</italic>, 2004</xref>; <xref ref-type="bibr" rid="b59">Weise <italic>et al</italic>, 2004</xref>). PrP<sup>C</sup> deficiency in mice increases infarct size following cerebral artery occlusion and increases caspase 3 activation (<xref ref-type="bibr" rid="b55">Spudich <italic>et al</italic>, 2005</xref>), and PrP<sup>C</sup> overexpression improves neurological behavior and reduces infarct volume in a rat stroke model (<xref ref-type="bibr" rid="b52">Shyu <italic>et al</italic>, 2005</xref>). Another widely observed and perhaps related phenomenon involves the ability of PrP<sup>C</sup> to protect against a variety of proapoptotic stimuli (<xref ref-type="bibr" rid="b25">Kuwahara <italic>et al</italic>, 1999</xref>; <xref ref-type="bibr" rid="b4">Bounhar <italic>et al</italic>, 2001</xref>; <xref ref-type="bibr" rid="b11">Chiarini <italic>et al</italic>, 2002</xref>; <xref ref-type="bibr" rid="b13">Cui <italic>et al</italic>, 2003</xref>; <xref ref-type="bibr" rid="b49">Sakudo <italic>et al</italic>, 2005</xref>; <xref ref-type="bibr" rid="b26">Lee <italic>et al</italic>, 2006</xref>; <xref ref-type="bibr" rid="b36">Novitskaya <italic>et al</italic>, 2006</xref>). Strong evidence for a neuroprotective activity for PrP<sup>C</sup> against apoptosis <italic>in vivo</italic> has come from studies of transgenic (Tg) mice expressing internally deleted forms of PrP or wild-type (wt)Dpl within the CNS. The presence of Dpl in the brain of <italic>Prnp</italic><sup>0/0</sup> mice leads to a neurodegenerative syndrome characterized by a profound apoptotic loss of cerebellar cells (<xref ref-type="bibr" rid="b35">Nishida <italic>et al</italic>, 1999</xref>; <xref ref-type="bibr" rid="b34">Moore <italic>et al</italic>, 2001</xref>; <xref ref-type="bibr" rid="b48">Rossi <italic>et al</italic>, 2001</xref>). A similar phenotype is observed when N-terminally truncated versions of PrP<sup>C</sup> (&#x00394;PrP) are expressed in the brain (<xref ref-type="bibr" rid="b51">Shmerling <italic>et al</italic>, 1998</xref>). Remarkably, both syndromes are abrogated by the coexpression of wt PrP<sup>C</sup>. Recently, it has been shown that a smaller deletion restricted to the well-conserved central domain of PrP is sufficient to elicit a highly toxic phenotype in <italic>Prnp</italic><sup>0/0</sup> mice (<xref ref-type="bibr" rid="b1">Baumann <italic>et al</italic>, 2007</xref>; <xref ref-type="bibr" rid="b27">Li <italic>et al</italic>, 2007</xref>). The above studies have led to a model in which Dpl and &#x00394;PrP initiate aberrant signaling through a hypothetical prion ligand termed L<sub>PrP</sub>, a process which is blocked by PrP<sup>C</sup> binding (<xref ref-type="bibr" rid="b16">Flechsig <italic>et al</italic>, 2004</xref>). Assuming that the interaction between PrP<sup>C</sup> and L<sub>PrP</sub> represents an essential physiological event, the authors also proposed the existence of a PrP<sup>C</sup>-like protein termed &#x003c0;, which binds to L<sub>PrP</sub> and is capable of compensating for the absence of PrP<sup>C</sup> in <italic>Prnp</italic><sup>0/0</sup> mice. To this date, no candidates for &#x003c0; (or L<sub>PrP</sub>) have been put forward. However, an open reading frame was discovered which, when translated, exhibits homology to the central hydrophobic domain in PrP<sup>C</sup>. This gene, denoted <italic>Sprn</italic> (&#x02018;shadow of the prion protein'), is present from zebrafish to humans and is predicted to encode a short protein, Shadoo (Sho) (<xref ref-type="bibr" rid="b44">Premzl <italic>et al</italic>, 2003</xref>). <italic>Sprn</italic> is located on chromosome 7 in mice, away from the <italic>Prn</italic> gene complex on chromosome 2.</p><p>Building on the genetic interaction between PrP<sup>C</sup> and Dpl or &#x00394;PrP, we have established an assay for PrP<sup>C</sup> activity in primary cultures of cerebellar granule cells (<xref ref-type="bibr" rid="b15">Drisaldi <italic>et al</italic>, 2004</xref>, and references therein). Here, cerebellar granule neurons (CGNs) cultured from <italic>Prnp</italic><sup>0/0</sup> mice are transfected with plasmids encoding Dpl or PrP alleles of interest and individual apoptotic events scored. This assay recapitulates the phenotypes produced by multiple PrP alleles in Tg mice, including neurotoxicity of both Dpl and &#x00394;PrP, and neuroprotective activity of PrP<sup>C</sup> against the toxicity elicited by either Dpl or &#x00394;PrP. In conjunction with biochemical and histological analyses, we have used the CGN assay to explore the properties of Sho. We now demonstrate that Sho is a GPI-anchored neuronal glycoprotein present in the CNS from early postnatal life. Not only is Sho PrP<sup>C</sup>-like in its ability to protect against both Dpl and &#x00394;PrP toxicity in the CGN assay, but it is also strikingly reduced in prion infections.</p></sec><sec disp-level="1"><title>Results</title><sec disp-level="2"><title>Sho protein expression in N2a cells and brain</title><p>Motivated by the absence of obvious phenotypic defects in adult <italic>Prnp</italic><sup>0/0</sup> mice, we considered proteins that might overlap functionally with PrP<sup>C</sup>. One criterion was evolutionary conservation. In this regard, bioinformatic analyses by Premzl and co-workers have yielded an interesting candidate in the shape of the <italic>Sprn</italic> open reading frame present in genomic DNA of species from mammals to fish (<xref ref-type="bibr" rid="b44">Premzl <italic>et al</italic>, 2003</xref>, <xref ref-type="bibr" rid="b43">2004</xref>; <xref ref-type="bibr" rid="b32">Miesbauer <italic>et al</italic>, 2006</xref>) and which, unlike the hypothetical <italic>Prnt</italic> gene (<xref ref-type="bibr" rid="b30">Makrinou <italic>et al</italic>, 2002</xref>; <xref ref-type="bibr" rid="b43">Premzl <italic>et al</italic>, 2004</xref>), is present in the mouse genome. The architecture of the predicted Sho protein loosely resembles the flexibly disordered PrP N-terminus (<xref ref-type="fig" rid="f1">Figure 1</xref>). Analyses of <italic>Sprn</italic> expression by RT&#x02013;PCR (<xref ref-type="bibr" rid="b44">Premzl <italic>et al</italic>, 2003</xref>) and interrogation of expressed sequence tag databases (UniGene) imply expression in embryonic and adult neuronal tissue as well as the retina and visual cortex, but have yet to document spliced mRNAs. Consequently, we evaluated Sho as a putative third member of the prion gene family.</p><p>To address expression at the protein level, we raised antibodies against Sho. Two antisera (&#x02018;04SH-1' and &#x02018;06SH-3') were against a mouse Sho peptide consisting of residues 86&#x02013;100, whereas a third (&#x02018;06rSH-1') was against full-length recombinant mouse Sho(25&#x02013;122) expressed in <italic>Escherichia coli</italic> (<xref ref-type="fig" rid="f2">Figure 2A</xref>) and recognizes an N-terminal epitope contained within residues 30&#x02013;61 (<xref ref-type="supplementary-material" rid="S1">Supplementary Figure S1</xref>). Assessed by Western blot of tissue lysates, 06rSH-1 was virtually devoid of cross-reactive species (<xref ref-type="supplementary-material" rid="S1">Supplementary Figure S1</xref>). Cross-reactive species of molecular weights incompatible with authentic Sho were present in analyses with antisera 04SH-1 and with 06SH-3, but these had varying intensities and/or different molecular weights for the two antisera. Consequently, the following comments are restricted to signals detected by two or more varieties of &#x003b1;-Sho antibodies.</p><p>Similar to PrP<sup>C</sup>, murine Sho is revealed as being expressed at the cell surface, <italic>N</italic>-glycosylated and sensitive to the GPI anchor cleaving enzyme phosphatidylinositol-specific phospholipase C (PI-PLC) in transfected N2a neuroblastoma cells (<xref ref-type="fig" rid="f2">Figure 2C&#x02013;E</xref>). Following PNGaseF treatment, full-length Sho has a molecular weight of 9.1 kDa as assessed by SDS&#x02013;PAGE (predicted 9.5 kDa). In addition to the full-length protein, a fraction of the protein in transfected N2a cells has a faster electrophoretic mobility (<xref ref-type="fig" rid="f2">Figure 2E</xref>). In PrP, a well-documented physiological &#x02018;C1' cleavage occurs just before the hydrophobic tract at residues His111 and Met112 (human PrP numbering scheme, underlined; <xref ref-type="fig" rid="f1">Figure 1</xref>) both in cultured cells and in the adult brain (<xref ref-type="bibr" rid="b38">Pan <italic>et al</italic>, 1992</xref>; <xref ref-type="bibr" rid="b10">Chen <italic>et al</italic>, 1995</xref>; <xref ref-type="bibr" rid="b58">Vincent <italic>et al</italic>, 2000</xref>). Since cell lysates for these analyses were prepared in the presence of protease inhibitors, it is possible that an analogous endoproteolytic processing could figure in the biogenesis of Sho. A detailed description of truncated forms of Sho will be presented elsewhere (Coomaraswamy <italic>et al</italic>, in preparation).</p><p>Analysis of mouse tissue by Western blotting defined a predominant glycosylated protein species of similar molecular weight to transfected full-length Sho (approximately 18 kDa), and one that is developmentally regulated, appearing at embryonic day 16 and persisting in early postnatal life and in the brains of adults (<xref ref-type="fig" rid="f3">Figure 3A and B</xref>). PNGaseF-sensitive bands of identical molecular weights were observed with two independent Sho antibodies, confirming the authenticity of the bands and the presence of Sho in the mouse CNS. Sho signal was emphasized in membrane-enriched preparations from adult mouse brains, corroborating its membrane anchorage (<xref ref-type="fig" rid="f3">Figure 3C</xref>). In Western blots performed with &#x003b1;-Sho86&#x02013;100 antisera, Sho signal increased following treatment with PNGaseF, suggesting that <italic>N</italic>-glycosylation at Asn107 partially occludes antibody binding at the adjacent epitope for the peptide-directed antiserum.</p></sec><sec disp-level="2"><title>Overlapping and complementary PrP<sup>C</sup>/Sho expression</title><p><italic>In situ</italic> hybridization using antisense-strand riboprobes prepared against the mouse <italic>Sprn</italic> open reading frame (but not sense-strand controls) yielded signals in the adult mouse CNS. Analyses of the hippocampus and cerebellum revealed prominent signals in the cell bodies of pyramidal cells and Purkinje cells, respectively (<xref ref-type="fig" rid="f4ah">Figure 4B</xref> and <xref ref-type="fig" rid="f4ip">J</xref>). By way of comparison, <italic>Prnp</italic> has a broader pattern of neuronal expression (<xref ref-type="bibr" rid="b24">Kretzschmar <italic>et al</italic>, 1986</xref>; <xref ref-type="bibr" rid="b57">Taraboulos <italic>et al</italic>, 1992</xref>). Immunohistochemistry for Sho protein yielded prominent signals in the same cell types defined by <italic>in situ</italic> hybridization (<xref ref-type="fig" rid="f4ah">Figure 4D</xref> and <xref ref-type="fig" rid="f4ip">L</xref>), that is, hippocampal neurons and cerebellar Purkinje cells. In the case of antisera 04SH-1, these signals were absent when antibodies were preincubated in a solution containing the Sho86&#x02013;100 peptide immunogen (<xref ref-type="fig" rid="f4ah">Figure 4C</xref> and <xref ref-type="fig" rid="f4ip">K</xref>). Besides defining Sho as the &#x02018;second' cellular prion protein present in neurons of the adult CNS, these data define intracellular transport phenomena, as immunohistochemical signals were present in cell processes in addition to the cell bodies detected by antisense riboprobes (i.e., predicted to contain Sho mRNA). In the case of Purkinje cells, immunostaining was present not only in cell bodies but also prominent in their processes, specifically in the dendritic arborizations present within the molecular layer of the cerebellum (<xref ref-type="fig" rid="f4ip">Figures 4L</xref> and <xref ref-type="fig" rid="f5">5F&#x02013;H</xref>, signals detected with all three antisera). A related phenomenon was observed in the hippocampus, notably in CA1 pyramidal neurons. Here, Sho immunoreactivity was absent from axonal projections (with all three &#x003b1;-Sho antibodies), present in cell bodies (seen by all three &#x003b1;-Sho antibodies), and notable in the apical dendritic processes located in the stratum radiatum of the hippocampus (strong signals with 04SH-1 and 06SH-3, and a less intense signal with 06rSH-1) (<xref ref-type="fig" rid="f4ah">Figures 4D</xref> and <xref ref-type="fig" rid="f5">5A&#x02013;C</xref>).</p><p>Since PrP has been reported to possess an unusual property for a GPI-linked protein, the ability to undergo basolateral (dendritic) sorting in polarized cells in distinction to the more typical apical (axonal) sorting, parallel analyses were undertaken for PrP<sup>C</sup> and Sho. PrP<sup>C</sup> was examined at basal levels from the (endogenous) <italic>Prnp</italic> gene, or expressed from a cosmid transgene of the hamster PrP gene including 25 kb of sequences 5&#x02032; to the transcriptional start-site (<xref ref-type="bibr" rid="b50">Scott <italic>et al</italic>, 1989</xref>; <xref ref-type="bibr" rid="b45">Prusiner <italic>et al</italic>, 1990</xref>). In the case of wt mouse PrP, analyses were performed with 7A12 antibody (<xref ref-type="bibr" rid="b28">Li <italic>et al</italic>, 2000</xref>) using <italic>Prnp</italic><sup>0/0</sup> mice as negative controls (<xref ref-type="fig" rid="f4ah">Figure 4E</xref> and <xref ref-type="fig" rid="f4ip">M</xref>), whereas non-Tg wt mice served as negative controls for the use of the hamster PrP transgene-specific 3F4 antibody (<xref ref-type="fig" rid="f4ah">Figure 4G</xref> and <xref ref-type="fig" rid="f4ip">O</xref>). Besides the anticipated differences in signal levels between wt and Tg(SHaPrP)7 mice, the PrP<sup>C</sup>-directed antibodies yielded similar expression patterns, with widespread staining throughout the brain. PrP<sup>C</sup> was underrepresented in the cell bodies of the pyramidal neurons of the hippocampus but abundantly present in the stratum oriens containing the axonal projections, and also in the radiatum, lacunosum moleculare and molecular layers (<xref ref-type="fig" rid="f4ah">Figure 4F and H</xref>). In the cerebellum, mouse PrP<sup>C</sup> was absent in wt Purkinje cells (as described previously (<xref ref-type="bibr" rid="b29">Liu <italic>et al</italic>, 2001</xref>; <xref ref-type="bibr" rid="b1">Baumann <italic>et al</italic>, 2007</xref>)) and hamster PrP<sup>C</sup> was represented in some but not all Purkinje cells of Tg(SHaPrP)7 mice, and at a level lower than that of the surrounding neuropil (<xref ref-type="fig" rid="f4ip">Figure 4N and P</xref>). On the other hand, PrP<sup>C</sup> was present in the granule cell layer and abundant in the molecular layer. Strikingly, the abundant signal present in the radiatum layer was not totally uniform, and&#x02014;by virtue of a negative staining effect&#x02014;revealed the outlines of Purkinje cell dendritic arborizations in the cerebellum and the apical dendritic of CA1 neurons (<xref ref-type="fig" rid="f5">Figure 5D&#x02013;E, and I&#x02013;J</xref>): these are structures with marked immunostaining with &#x003b1;-Sho86&#x02013;100 (04SH-1 and 06SH-3) and &#x003b1;-rSho (06-rSH1); <xref ref-type="fig" rid="f5">Figure 5A&#x02013;C and F&#x02013;H</xref>). These data therefore define a complementary &#x02018;interlocking' aspect to PrP<sup>C</sup>/Sho protein expression in the cerebellum and suggest a similar effect in the hippocampus.</p><p>Although the most prominent Sho signals were obtained in the hippocampus and cerebellum (<xref ref-type="fig" rid="f4ah">Figure 4</xref>), signals for both <italic>Sprn</italic> mRNA and Sho protein were also present in other areas of the brain including the cerebral cortex, the thalamus, and the medulla (<xref ref-type="fig" rid="f5">Figure 5L&#x02013;N</xref>; <xref ref-type="supplementary-material" rid="S1">Supplementary Figure S2</xref>). Coincidence with neurofilament staining indicates that neurons are the prominent site of Sho expression (<xref ref-type="supplementary-material" rid="S1">Supplementary Figure S2</xref>). PrP<sup>C</sup> signal was abundant in these regions (<xref ref-type="fig" rid="f5">Figure 5</xref>, and data not shown), confirming that Sho and PrP<sup>C</sup> expression profiles overlap in certain areas of the brain. A further example of this phenomenon is apparent in the adult retina (<xref ref-type="bibr" rid="b44">Premzl <italic>et al</italic>, 2003</xref>; Chishti <italic>et al</italic>, in preparation). In overview, Sho expression within the adult mouse brain is either less widespread than PrP<sup>C</sup>, or basal Sho levels in certain areas fall below the detection threshold of our current procedures. Lastly, to assess whether there is a physiological cross-regulation effect between PrP<sup>C</sup> and Sho, we performed a number of analyses on <italic>Prnp</italic><sup>0/0</sup> mice (<xref ref-type="supplementary-material" rid="S1">Supplementary Figure S4</xref>). These failed to reveal a clear upregulation of Sho in response to PrP<sup>C</sup> deficiency.</p></sec><sec disp-level="2"><title>Neuroprotective activity and the central region of PrP</title><p>Two N-terminal PrP modules, the charged region and the copper-binding octarepeats, contribute to neuroprotective activity in a neuronal assay (<xref ref-type="bibr" rid="b15">Drisaldi <italic>et al</italic>, 2004</xref>). However, while others analyzed the same N-terminal modules, they highlighted a trafficking effect (<xref ref-type="bibr" rid="b56">Sunyach <italic>et al</italic>, 2003</xref>), so we sought determinants beyond these potential delivery signals. The C-terminus of PrP<sup>C</sup> comprises a three-helix bundle (<xref ref-type="bibr" rid="b46">Riek <italic>et al</italic>, 1996</xref>) similar to Dpl (<xref ref-type="bibr" rid="b33">Mo <italic>et al</italic>, 2001</xref>), and in the form of alleles such as PrP&#x00394;32&#x02013;121 (<xref ref-type="bibr" rid="b51">Shmerling <italic>et al</italic>, 1998</xref>), exhibits Dpl-like toxicity. We therefore focused on the &#x02018;remaining' area of PrP, residues 91&#x02013;121 between the octarepeats and the structured domain (<xref ref-type="fig" rid="f1">Figure 1</xref>) containing the hydrophobic domain (HD) with Sho homology. The deletion alleles were tested for their ability to engender stable forms of PrP. As anticipated from prior analyses of in-frame deletions (<xref ref-type="bibr" rid="b20">Holscher <italic>et al</italic>, 1998</xref>; <xref ref-type="bibr" rid="b51">Shmerling <italic>et al</italic>, 1998</xref>; <xref ref-type="bibr" rid="b18">Hegde <italic>et al</italic>, 1999</xref>), these forms of PrP were synthesized at levels similar to wt PrP, and also underwent similar maturation (<xref ref-type="bibr" rid="b1">Baumann <italic>et al</italic>, 2007</xref>; <xref ref-type="bibr" rid="b27">Li <italic>et al</italic>, 2007</xref>) (<xref ref-type="supplementary-material" rid="S1">Supplementary Figure S3</xref>).</p><p>Residues 100&#x02013;105 are poorly conserved (<xref ref-type="fig" rid="f1">Figure 1</xref>) and in the <underline>c</underline>erebellar <underline>g</underline>ranule <underline>n</underline>euron (CGN) cellular assay (<xref ref-type="bibr" rid="b15">Drisaldi <italic>et al</italic>, 2004</xref>), a PrP&#x00394;100&#x02013;105 allele exhibited protective activity like wt PrP (<italic>P</italic>&#x0003c;0.001) when measured against Dpl. Conversely, PrP&#x00394;91&#x02013;99 and PrP&#x00394;106&#x02013;112 alleles had decreased protective activity (neither is significantly different from Dpl alone; <xref ref-type="fig" rid="f6">Figure 6B</xref>). PrP&#x00394;106&#x02013;121 transfected alone exhibited partial neurotoxic activity approaching that of a toxic PrP&#x00394;32&#x02013;121 control allele (<xref ref-type="bibr" rid="b51">Shmerling <italic>et al</italic>, 1998</xref>), but different from that of wt PrP (<italic>P</italic>&#x0003c;0.01) (<xref ref-type="fig" rid="f6">Figure 6A</xref>). These data offer a parallel to assays in Tg mice. Here, deletions invading the PrP central region from residues 91 to 121 produce proteins that are progressively toxic: no significant pathological abnormalities are noted in Tg mice expressing PrP &#x00394;32&#x02013;80, &#x00394;32&#x02013;93, and &#x00394;32&#x02013;106, but mice expressing &#x00394;32&#x02013;121 (or &#x00394;32&#x02013;134) exhibit profound loss of cerebellar cells (<xref ref-type="bibr" rid="b51">Shmerling <italic>et al</italic>, 1998</xref>; <xref ref-type="bibr" rid="b16">Flechsig <italic>et al</italic>, 2004</xref>), as do mice expressing PrP&#x00394;94&#x02013;134 or &#x00394;105&#x02013;125 (<xref ref-type="bibr" rid="b1">Baumann <italic>et al</italic>, 2007</xref>; <xref ref-type="bibr" rid="b27">Li <italic>et al</italic>, 2007</xref>). From this we infer that a third determinant of neuroprotection lies between PrP residues 91 and 99, and a complex or modular activity determinant (&#x02018;determinant 4') lies between residues 106&#x02013;121, whereby a &#x00394;106&#x02013;112 deletion loses protective activity and a larger &#x00394;106&#x02013;121 deletion exhibits partial neurotoxic activity. These data extend observations made in hippocampal neurons, where PrP residues 95&#x02013;124 were implicated in neuroprotective action versus Dpl (<xref ref-type="bibr" rid="b26">Lee <italic>et al</italic>, 2006</xref>).</p></sec><sec disp-level="2"><title>Sho has PrP<sup>C</sup>-like neuroprotective activity in a functional assay</title><p>Sequence identity between Sho and PrP occurs in the central hydrophobic region. Since this area is highly conserved in PrP (<xref ref-type="bibr" rid="b60">Wopfner <italic>et al</italic>, 1999</xref>) and is predicted to overlap or be immediately adjacent to determinants of neuroprotective action (<xref ref-type="fig" rid="f1">Figures 1</xref> and <xref ref-type="fig" rid="f6">6B</xref>), we tested Sho in a functional assay in <italic>Prnp</italic><sup>0/0</sup> CGN cultures. Remarkably, a wt mouse Sho cDNA was PrP<sup>C</sup>-like in its ability to block the proapoptotic action of cotransfected Dpl (<xref ref-type="fig" rid="f6">Figure 6B</xref>) (<italic>P</italic>&#x0003c;0.001 versus Dpl alone, no significant difference between wt PrP alone versus Dpl&#x0002b;Sho). Since the putative PrP<sup>C</sup>-like activity called &#x003c0; was inferred from the action of &#x00394;PrP, rather than the action of Dpl (<xref ref-type="bibr" rid="b51">Shmerling <italic>et al</italic>, 1998</xref>), further experiments were carried out to assess the effect of Sho upon the toxic action of a &#x00394;PrP allele (<xref ref-type="fig" rid="f6">Figure 6C</xref>). In these cotransfections, wt Sho reduced the toxic activity of singly transfected PrP&#x00394;32&#x02013;121 to a baseline defined by &#x02018;empty vector' (pBUD.GFP) controls (<italic>P</italic>&#x0003c;0.001), and overlapping expression and colocalization was apparent in transfected neurons (<xref ref-type="fig" rid="f6">Figure 6E</xref>). Besides adding to the similarities between Sho and &#x003c0;, these data underscore the notion that &#x00394;PrP and Dpl exert toxicity through the same pathway.</p><p>Given the similarity between Sho and PrP in the HD, this domain was a strong candidate for the &#x02018;active site' of Sho. Consequently, we assessed the protective activity of Sho bearing a precise HD deletion. Here, the cotransfected Sho&#x00394;62&#x02013;77 allele was not protective against Dpl (not significant versus Dpl alone) (<xref ref-type="fig" rid="f6">Figure 6B</xref>). wt and &#x00394;62&#x02013;77 Sho alleles are expressed at similar levels in bulk-transfected cells, and with immunoreactivity present upon the surface of transfected N2a cells (<xref ref-type="fig" rid="f2">Figure 2C</xref>; <xref ref-type="supplementary-material" rid="S1">Supplementary Figure S1</xref>). In contrast to a wt control allele, the Sho&#x00394;62&#x02013;77 allele also did not exert significant protection against a toxic PrP&#x00394;32&#x02013;121 allele (<italic>P</italic>&#x0003c;0.001 versus baseline of pBUD.GFP empty vector; <xref ref-type="fig" rid="f6">Figure 6C</xref>).</p><p>As an extrapolation from results presented above and from prior analyses (<xref ref-type="bibr" rid="b35">Nishida <italic>et al</italic>, 1999</xref>; <xref ref-type="bibr" rid="b34">Moore <italic>et al</italic>, 2001</xref>; <xref ref-type="bibr" rid="b48">Rossi <italic>et al</italic>, 2001</xref>), the ability of Dpl to cause cell death in <italic>Prnp</italic><sup>0/0</sup> CGNs implies lack of a compensatory neuroprotective activity (e.g., Sho) in these cells. To test this inference, and as an additional control for immunohistochemical analyses presented in <xref ref-type="fig" rid="f4ah">Figures 4</xref> and <xref ref-type="fig" rid="f5">5</xref>, we assessed Sho expression in the lysates of purified CGNs. Although Sho was readily detected in brain lysate, the analysis failed to detect a comparable signal in a normalized loading of CGN lysate (<xref ref-type="fig" rid="f6">Figure 6D</xref>).</p></sec><sec disp-level="2"><title>Sho expression in prion-infected brains</title><p>To assess Sho in a disease setting, Western blots were performed on brain homogenates from wt mice infected with the RML isolate of mouse-adapted prions (<xref ref-type="bibr" rid="b9">Carlson <italic>et al</italic>, 1986</xref>). Two independent cohorts produced in different laboratories were used for this analysis. Assessed in the clinical phase of disease, animals from both cohorts demonstrated a striking reduction in Sho protein levels (<xref ref-type="fig" rid="f7">Figure 7A and E</xref>). Notably, this decrease in signal is apparent using two distinct Sho antibodies with independent epitopes. Normalized against Thy-1, another GPI-anchored neuronal protein, Sho signals of RML-inoculated brain extracts versus brain extracts from healthy controls were reduced eight-fold (<xref ref-type="fig" rid="f7">Figure 7B</xref>). A variety of other neuronal proteins were probed as internal controls (<xref ref-type="fig" rid="f7">Figure 7C</xref>). Although mild loss of signal was apparent for some of these&#x02014;perhaps a direct consequence of neuronal damage and death&#x02014;in no instance did these reductions approach those seen for Sho. As a further control we assessed Sho levels in a widely used animal model of Alzheimer's Disease, TgCRND8 mice expressing a mutant &#x003b2;-amyloid precursor protein transgene (<xref ref-type="bibr" rid="b12">Chishti <italic>et al</italic>, 2001</xref>). Using mice in clinical phase of the disease (marked by overt amyloid deposits, normalized A&#x003b2; levels equaling those of sporadic Alzheimer's disease, and profound cognitive impairment), no difference was apparent between TgCRND8 and non-Tg mice with regards to Sho levels (<xref ref-type="fig" rid="f7">Figure 7D</xref>). Thus, depletion of Sho is absent in non-infectious CNS amyloidosis.</p></sec></sec><sec disp-level="1"><title>Discussion</title><p>Our first conclusion is that Sho is a bona fide neuronal glycoprotein and the third member of the mammalian prion protein family. Beyond mere sequence homology, Sho demonstrates a number of biochemical and cell biological properties also exhibited by PrP<sup>C</sup>. These include addition of a GPI anchor, <italic>N</italic>-glycosylation at one or two sites and a cleavage event likely positioned N-terminal to the hydrophobic tract (<xref ref-type="fig" rid="f1">Figures 1</xref> and <xref ref-type="fig" rid="f2">2C&#x02013;E</xref>; <xref ref-type="supplementary-material" rid="S1">Supplementary Figure S1</xref>). Furthermore, there are functional redundancies between PrP<sup>C</sup> and Sho measured in CGN cells. Although Sho and PrP<sup>C</sup> have dissimilar N-terminal regions that may tailor their activities in different neuroanatomic sites, we infer that the center of both PrP<sup>C</sup> and Sho comprises a functionally conserved and ancient activity domain contributing to neuroprotection. In PrP<sup>C</sup>-deficient areas of the brain, Sho may be particularly important in filling-in a PrP-like activity. Although the exact relevance of PrP<sup>C</sup>/Sho neuroprotection against exogenous stimuli versus <italic>in vivo</italic> brain physiology remains to be deciphered, a role against neuronal insults such as ischemic damage seems plausible. Indeed, increased PrP<sup>C</sup> expression following stroke has been observed in both humans and mice (<xref ref-type="bibr" rid="b31">McLennan <italic>et al</italic>, 2004</xref>; <xref ref-type="bibr" rid="b59">Weise <italic>et al</italic>, 2004</xref>).</p><p>A second conclusion is that the study of Sho may help decipher the molecular mechanisms underlying physiological signaling from the prion protein family. Here, some initial hints can be inferred from mutational analysis. As deletions invade the central region of PrP<sup>C</sup>, not only is protective activity lost, but the mutant PrPs gain spontaneous proapoptotic activity, as shown by loss of the granule cell layer in Tg mice (<xref ref-type="bibr" rid="b16">Flechsig <italic>et al</italic>, 2004</xref>), and echoed here by the divergent performance of PrP&#x00394;106&#x02013;112 and &#x00394;106&#x02013;121 alleles in the CGN assay. It is possible that a gain of proapoptotic function for PrP within CA1 neurons when it is sterically blocked and dimerized by antibodies against residues 95&#x02013;105 proceeds by a related mechanism (<xref ref-type="bibr" rid="b54">Solforosi <italic>et al</italic>, 2004</xref>). In any event, the PrP<sup>C</sup> central region defined by genetic mapping (analyzed by CGN assays in this paper, see also <xref ref-type="bibr" rid="b26">Lee <italic>et al</italic>, 2006</xref>) is natively unstructured in NMR studies (<xref ref-type="bibr" rid="b14">Donne <italic>et al</italic>, 1997</xref>; <xref ref-type="bibr" rid="b47">Riek <italic>et al</italic>, 1997</xref>) and the homologous region in Sho is likely to be natively unstructured as well (<xref ref-type="fig" rid="f2">Figure 2B</xref>). This region may serve as a site for protein&#x02013;protein interactions, and in this regard, our results parallel and extend a model for signaling from PrP<sup>C</sup> protein complexes. Besides PrP<sup>C</sup>, this model involves a hypothetical ligand, L<sub>PrP</sub>, and a conjectural PrP<sup>C</sup>-like protein denoted &#x02018;&#x003c0;' (<xref ref-type="bibr" rid="b51">Shmerling <italic>et al</italic>, 1998</xref>; <xref ref-type="bibr" rid="b16">Flechsig <italic>et al</italic>, 2004</xref>). Two docking sites are posited between L<sub>PrP</sub> and PrP<sup>C</sup>, and one docking site between Dpl or &#x00394;PrP and L<sub>PrP</sub>. Based on sequence similarity and domain structure (<xref ref-type="fig" rid="f1">Figure 1</xref>), biochemical properties (<xref ref-type="fig" rid="f2">Figure 2</xref>), a low level expression of Sho in the cerebellar granule cells (<xref ref-type="fig" rid="f4ip">Figures 4L</xref> and <xref ref-type="fig" rid="f6">6D</xref>), and similar effects of wt PrP or Sho versus Dpl or PrP&#x00394;32&#x02013;121 in CGN assays (<xref ref-type="bibr" rid="b15">Drisaldi <italic>et al</italic>, 2004</xref>) (<xref ref-type="fig" rid="f6">Figure 6B</xref>), Sho can be seen to resemble &#x003c0;. In this scheme, sequences within or around the hydrophobic domain of Sho or PrP<sup>C</sup> would comprise a docking site for L<sub>PrP</sub>, a site associated with a protective effect. In PrP<sup>C</sup>, partial loss of this site may confer spontaneous neurotoxic behavior, consistent with the enhanced toxicity observed in Tg mice expressing PrP with HD deletions (<xref ref-type="bibr" rid="b1">Baumann <italic>et al</italic>, 2007</xref>; <xref ref-type="bibr" rid="b27">Li <italic>et al</italic>, 2007</xref>). A second site lying within the &#x003b1;-helical domain present in PrP, &#x00394;PrP and Dpl is associated with a toxic effect (i.e., as per &#x00394;PrP and Dpl) unless the first site is also present (as in wt PrP<sup>C</sup>) (<xref ref-type="bibr" rid="b51">Shmerling <italic>et al</italic>, 1998</xref>; <xref ref-type="bibr" rid="b13">Cui <italic>et al</italic>, 2003</xref>; <xref ref-type="bibr" rid="b15">Drisaldi <italic>et al</italic>, 2004</xref>). Even though the original L<sub>PrP</sub>&#x02013;PrP<sup>C</sup>&#x02013;&#x003c0; model may prove incorrect in a cell biological sense (i.e., that signaling may have more to do with protection from toxic stimuli rather than regulation of endogenous trophic signals), it provides a useful framework for deciphering molecular interactions. Certainly the ability to now perform studies with PrP, &#x00394;PrP, Dpl and Sho and assess responses within a cellular assay should aid the identification of authentic PrP interactors.</p><p>A third conclusion is that Sho may open a window to pathological signaling events in prion disease. Studies of scrapie-infected rodents support the concept of neuroanatomic &#x02018;target areas' that give rise to the clinical features of disease (<xref ref-type="bibr" rid="b23">Kimberlin and Walker, 1986</xref>). Thus far, the mechanisms by which disease associated forms of PrP (PrP<sup>Sc</sup> or &#x02018;PrP<sup>D</sup>') might cause dysfunction in these target areas have proven elusive (<xref ref-type="bibr" rid="b17">Flechsig <italic>et al</italic>, 2000</xref>). For example, whereas a requirement for PrP<sup>C</sup> was inferred from grafting tissue from mice overexpressing PrP<sup>C</sup> into <italic>Prnp</italic><sup>0/0</sup> mouse brains and performing prion challenge of chimeric mice (<xref ref-type="bibr" rid="b5">Brandner <italic>et al</italic>, 1996</xref>), a genetic reconstitution experiment employing an astrocyte-specific hamster PrP transgene demonstrated an opposite effect, namely neuronal damage in PrP<sup>C</sup>-deficient neurons upon prion challenge (<xref ref-type="bibr" rid="b21">Jeffrey <italic>et al</italic>, 2004</xref>). The concept of pathogenesis <italic>in trans</italic>, that is, independent of PrP<sup>C</sup> expression, is underlined by prior studies and by experiments herein, which demonstrate that the dendrites of CA1 neurons, an early &#x02018;clinical target area' in prion infections, are largely devoid of PrP<sup>C</sup> (<xref ref-type="fig" rid="f5">Figure 5D and E</xref>). Susceptibility of dendritic structures in this neuroanatomic area has been demonstrated by several techniques in different models of infectious prion disease (<xref ref-type="bibr" rid="b19">Hogan <italic>et al</italic>, 1987</xref>; <xref ref-type="bibr" rid="b22">Johnston <italic>et al</italic>, 1997</xref>; <xref ref-type="bibr" rid="b6">Brown <italic>et al</italic>, 2001</xref>). We note that these structures are strongly labeled by both Sho peptide directed antisera in wt mice (<xref ref-type="fig" rid="f5">Figure 5A and B</xref>), and are distorted and attenuated in prion-infected mice (not shown), as already described by others (<xref ref-type="bibr" rid="b19">Hogan <italic>et al</italic>, 1987</xref>; <xref ref-type="bibr" rid="b22">Johnston <italic>et al</italic>, 1997</xref>; <xref ref-type="bibr" rid="b6">Brown <italic>et al</italic>, 2001</xref>).</p><p>Strikingly, Western blot analyses of brains from clinically ill prion-infected mice revealed a dramatic reduction of Sho protein (<xref ref-type="fig" rid="f7">Figure 7</xref>). Because Sho has neuroprotective properties (<xref ref-type="fig" rid="f6">Figure 6</xref>), it seems reasonable to consider whether a loss of Sho may underlie some of the clinical or pathological features of prion disease. In this regard, future studies utilizing <italic>Sprn</italic><sup>0/0</sup> mice should prove informative. The mechanism governing the loss of Sho protein during prion infections remains to be determined. While a transcriptional effect seems unlikely (not shown), protein structure may play a role. Since Sho's conserved region coincides with the epicenter of PrP<sup>C</sup> misfolding to disease-associated forms such as PrP<sup>Sc</sup> (<xref ref-type="bibr" rid="b41">Peretz <italic>et al</italic>, 1997</xref>, <xref ref-type="bibr" rid="b40">2001</xref>; <xref ref-type="bibr" rid="b3">Beringue <italic>et al</italic>, 2004</xref>), conformational alterations in unstructured, cell-anchored Sho (or in Sho shed into the parenchyma, like other GPI-anchored proteins; <xref ref-type="bibr" rid="b39">Parkin <italic>et al</italic>, 2004</xref>) may occur upon interaction with PrP<sup>Sc</sup>. However, this does not explain how altered Sho proteins, should they exist, might be more prone to degradation. Expanding the view to include the concept of aberrant signaling may provide a more useful take on this problem. Assuming that Sho exerts a neuroprotective function, perturbations in this protective pathway could destabilize Sho or lead to a loss of Sho-expressing cells and a commensurate drop in protein level. According to this hypothesis, parenchymal PrP<sup>Sc</sup> might interfere with the physiological protective activity of Sho <italic>in trans</italic> by virtue of both its aberrant fold and cell biological resemblance to Sho. While new experiments will be required to probe the validity of these concepts and the mechanisms controlling Sho expression, we suggest that Sho is a potential modulator for the biological actions of normal and abnormal PrP.</p></sec><sec disp-level="1" sec-type="materials|methods"><title>Materials and methods</title><sec disp-level="2"><title>Bioinformatics and statistics</title><p>Protein alignments were created using the T-COFFEE algorithm and EST searches conducted using UniGene. Data sets for all transfected constructs were assessed for normality (<italic>P</italic>&#x0003e;0.10) by the Kolmogorov&#x02013;Smirnov test and analyzed by one-way ANOVA, Tukey pairwise comparisons, with significance set at <italic>P</italic>&#x0003c;0.05, using Prism software (v4.0c, GraphPad Inc.).</p></sec><sec disp-level="2"><title>Mouse lines, husbandry and inoculations</title><p><italic>Zrch I Prnp</italic><sup>0/0</sup> mice and littermates were maintained on a C57/B6 congenic background. Mice for inoculations, either C3H/B6 hybrids (Toronto) or B6 inbred (McLaughlin Research Institute) were inoculated intracerebrally with 30 &#x003bc;l of 0.1&#x00025; RML-infected brain homogenate diluted in phosphate-buffered saline (PBS) containing BSA (50 mg/ml), penicillin (0.5 U/ml) and streptomycin (0.5 &#x003bc;g/ml). Age-matched non-inoculated or mice inoculated with normal brain comprised negative controls. Clinically ill mice were killed and 10&#x00025; brain homogenates in PBS were prepared. Proteinase K digestions (50 &#x003bc;g/ml) were performed at 37&#x000b0;C for 1 h. Sho levels were calculated by densitometry (Scion Image) and comparison to a standard curve created from serial dilutions of non-infected brain homogenate. TgCRND8 mice (<xref ref-type="bibr" rid="b12">Chishti <italic>et al</italic>, 2001</xref>) on a C3H/C57BL6 outbred background were killed at clinical illness (&#x0223c;8 months) and 10&#x00025; brain homogenates prepared in 0.32 M sucrose containing protease inhibitors.</p></sec><sec disp-level="2"><title>Plasmid generation and recombinant protein</title><p>The Sho open reading frame was amplified from mouse genomic DNA and inserted between the <italic>Hin</italic>dIII and <italic>Xba</italic>I sites of either pcDNA3 or pBUD.CE4. GFP (Invitrogen). PrP and Sho mutants were generated using methods previously described (<xref ref-type="bibr" rid="b15">Drisaldi <italic>et al</italic>, 2004</xref>), with constructs verified by DNA sequencing (details available on request). cDNA encoding residues 25&#x02013;122 of the mouse protein was amplified from pcDNA3.Sho and inserted between the <italic>Nde</italic>I and <italic>Bam</italic>HI sites of the pET-19b vector (Novagen) and expressed in <italic>E. coli</italic> BL21(DE3)/RIL (Stratagene). Following induction and lysis, filtered lysate was subjected to Ni<sup>2&#x0002b;</sup> affinity chromatography (Qiagen), eluted with 250 mM imidazole and dialyzed into 20 mM Tns&#x02013;Hcl pH8.0, 100 mM NaCl. The polyhistidine tag was removed with enterokinase (Roche). Purity was assessed by SDS&#x02013;PAGE and concentration estimated using bovine serum albumin standards. Far-UV circular dichroism spectra of recombinant Sho in PBS pH 7.0 and a protein concentration of 0.1 mg/ml were collected at 22&#x000b0;C using a Jasco J-715 spectropolarimeter.</p></sec><sec disp-level="2"><title>Sho antibody production</title><p>The peptide CRRTSGPGELGLEDDE (Sho residues 86&#x02013;100 plus an N-terminal cysteine) was conjugated to maleimide-activated KLH (Pierce) and injected into New Zealand White rabbits. Alternatively, recombinant Sho was conjugated to KLH using EDC (1-ethyl-3-&#x0005b;3-dimethylaminopropyl&#x0005d; carbodiimide hydrochloride) chemistry (Pierce) and injected into rabbits. Antibodies were precipitated from serum using ammonium sulfate and then affinity purified using the respective peptide (SulfoLink column) or polypeptide (AminoLink Plus Coupling Gel column) immunogens. Epitope positions are shown in <xref ref-type="fig" rid="f2">Figure 2</xref>.</p></sec><sec disp-level="2"><title>Cell culture and PI-PLC treatment</title><p>N2a cells, HEK293 and CGN cells were cultured, transfected and lysed as described previously (<xref ref-type="bibr" rid="b15">Drisaldi <italic>et al</italic>, 2004</xref>), except that staining for an activated caspase 3 neo-epitope (Cell Signaling Technology) was used to quantify apoptotic events and conditioned medium from adjacent wells replaced medium on transfected cells. CGN assays represent two or more independent triplicate transfections into <italic>Prnp</italic><sup>0/0</sup> cells, with observers being blind to the genotype of transfected test plasmids. For PIPLC treatment, 24 h post-transfection, Sho-transfected N2a cells were washed three times with PBS, and then treated with PI-PLC (Invitrogen) diluted in PBS for 40 min at 4&#x000b0;C. Cells were then washed twice and lysed as above.</p></sec><sec disp-level="2"><title>Immunocytochemistry and immunohistochemistry</title><p>N2a or HEK293 cells 24 h post-transfection were washed with PBS, fixed with 4&#x00025; paraformaldehyde, washed with PBS, blocked with 2&#x00025; goat serum, then incubated with either Sho antibody (04SH-1, 6 &#x003bc;g/ml) or PrP antibody (8H4, 1 &#x003bc;g/ml), overnight at 4&#x000b0;C. Following PBS washes, cells were incubated with AlexaFluor488- or AlexaFluor594-conjugated secondary antibodies (Invitrogen; 1:300) for 2 h and then washed three times with PBS. For tissue analysis, mice were saline-perfused. Brains were fixed in Carnoy's fixative (10&#x00025; glacial acetic acid, 60&#x00025; methanol, 30&#x00025; chloroform) bisected and processed. Six-micrometer sections were dried, deparaffinized and taken to TBS (pH 7.2) for incubation with primary antibody at 4&#x000b0;C (anti-Sho 04SH-1 (1:100, this paper), anti-Sho 06SH-3 (1:200, this paper), anti-Sho 06rSH-1 (1:50, this paper), anti-PrP 3F4 (1:20 000; Signet), anti-PrP 7A12 (1:10 000; <xref ref-type="bibr" rid="b28">Li <italic>et al</italic>, 2000</xref>), and anti-calbindin D-28K (1:2000; Chemicon). Other antibodies used include anti-Thy-1, R194 (a generous gift from Roger Morris); anti-NSE, rabbit polyclonal from Polysciences Inc.; anti-synaptophysin, SY38 from Chemicon; anti-actin, rabbit polyclonal from Sigma (20&#x02013;33); and anti-neurofilament H, SMI-32 from Sternberger Monoclonals Inc. For peptide blocking of antibody reactivity, peptide was added in four-fold mass excess to Sho antibody and incubated overnight at 4&#x000b0;C before use. Sections were rinsed in TBS and processed in DakoCytomation EnVision Labelled Polymer, visualized with DAB (3,3&#x02032;-diaminobenzidine) and counterstained with Harris' hematoxylin. Images were obtained with a Leica DM6000B microscope using a Micropublisher 3.3RTV camera (Q Imaging Inc.) and OpenLab4.0.4 software (Improvision). Images in <xref ref-type="fig" rid="f5">Figures 5L, M</xref> and <xref ref-type="fig" rid="f6">6E</xref> were de-convoluted using the iterative restoration function in Volocity. For fluorescent double labeling experiments, the secondary antibodies used were AlexaFluor-488 (green) and AlexaFluor-594 (red)-conjugated antibodies (Invitrogen). For immunocytochemistry on CGNs (<xref ref-type="fig" rid="f6">Figure 6E</xref>), cells were fixed 24 h post-transfection in ice-cold methanol for 5 min at &#x02212;20&#x000b0;C, and then processed and stained.</p></sec><sec disp-level="2"><title><italic>In situ</italic> hybridization</title><p>pcDNA3.Sho plasmid was linearized with <italic>Hin</italic>dIII or <italic>Bgl</italic>II to generate antisense and sense probes, respectively, using the DIG RNA labeling kit (Roche). Sections (6 &#x003bc;m) of formalin-fixed brains were cut using an RNase-free blade, mounted and dried overnight at 63&#x000b0;C. Tissue processing and <italic>in situ</italic> hybridization was performed as described by <xref ref-type="bibr" rid="b42">Peterson <italic>et al</italic> (2004)</xref>. DIG-labeled RNA probes were diluted 1/200&#x02013;1/400 in hybridization buffer. Alkaline phosphate substrate NBT/BCIP was added, color development performed for 16 h in the dark and slides mounted without counterstaining.</p></sec><sec disp-level="2"><title>Brain preparation and Western blotting</title><p>Mouse whole-brain homogenates were prepared in 0.32 M sucrose containing complete protease inhibitor cocktail (Invitrogen). For preparation of crude membranes, homogenates were spun at 700 <italic>g</italic> for 10 min at 4&#x000b0;C, pellets washed with 1 volume of homogenization buffer, spun again as above, supernatants were pooled then spun at 100 000 <italic>g</italic> for 1 h at 4&#x000b0;C and pellets resuspended in cold 50 mM Tris&#x02013;HCl, pH 7.4, 150 mM NaCl, 1 mM EDTA, 1&#x00025; Triton X-100. After spinning (100 000 <italic>g</italic>, 1 h, 4&#x000b0;C) the supernatant was stored at &#x02212;80&#x000b0;C. Protein was separated on either NuPAGE 4&#x02013;12&#x00025; gels (Invitrogen) using the MES buffer system, or by conventional SDS&#x02013;PAGE using 14&#x00025; polyacrylamide gels and transferred to either nitrocellulose (PrP blots, 3&#x00025; BSA block) or PVDF (Sho blots, 5&#x00025; non-fat skim milk block). Blots were incubated overnight with primary antibodies (D13 or D18 at 0.5 &#x003bc;g/ml for PrP (InPro Inc.), or 04SH-1 or 06rSH-1 Sho polyclonals at 1:500 or 1:2000, respectively, incubated with HRP-conjugated secondary antibody and developed using &#x02018;Western Lightning' ECL (Perkin-Elmer). The embryo blot was supplied from Zyagen (San Diego, CA), probed with 04SH-1 and then stripped using 0.2 M glycine pH 2.2, 1&#x00025; Tween-20, 0.1&#x00025; SDS, followed by reprobing with D13 antibody</p></sec></sec><sec sec-type="supplementary-material" id="S1"><title>Supplementary Material</title><supplementary-material id="N0x1c0bd10N0x31ffdf0" content-type="local-data"><caption><p>Supplementary Figures</p></caption><media mimetype="application" mime-subtype="pdf" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="7601830s1.pdf"/></supplementary-material></sec></body><back><ack><p>This work was supported by the Canadian Institutes of Health Research (Grants MOP36377 and MSC46763) and a fellowship to JCW from the Natural Sciences and Engineering Research Council of Canada (PGSD2-319161-2005). We also acknowledge the travel grants from the CIHR-Strategic Training in Health Research (STIHR) initiative and the Canadian Network Centres of Excellence (&#x02018;PrioNet'). DW is an Alberta Prion Research Institute Scholar. We thank Nathalie Daude and Agnes Lau for bioinformatic analyses, and Janice Robertson, Julie Forman-Kay and Rod Bremner for discussions.</p></ack><ref-list><ref id="b1"><citation citation-type="journal"><name><surname>Baumann</surname><given-names>F</given-names></name>, <name><surname>Tolnay</surname><given-names>M</given-names></name>, <name><surname>Brabeck</surname><given-names>C</given-names></name>, <name><surname>Pahnke</surname><given-names>J</given-names></name>, <name><surname>Kloz</surname><given-names>U</given-names></name>, <name><surname>Niemann</surname><given-names>HH</given-names></name>, <name><surname>Heikenwalder</surname><given-names>M</given-names></name>, <name><surname>Rulicke</surname><given-names>T</given-names></name>, <name><surname>Burkle</surname><given-names>A</given-names></name>, <name><surname>Aguzzi</surname><given-names>A</given-names></name> (<year>2007</year>) <article-title>Lethal recessive myelin toxicity of prion protein lacking its central domain</article-title>. <source>EMBO J</source><volume>26</volume>: <fpage>538</fpage>&#x02013;<lpage>547</lpage><pub-id pub-id-type="pmid">17245436</pub-id></citation></ref><ref id="b2"><citation citation-type="journal"><name><surname>Behrens</surname><given-names>A</given-names></name>, <name><surname>Genoud</surname><given-names>N</given-names></name>, <name><surname>Naumann</surname><given-names>H</given-names></name>, <name><surname>R&#x000fc;licke</surname><given-names>T</given-names></name>, <name><surname>Janett</surname><given-names>F</given-names></name>, <name><surname>Heppner</surname><given-names>FL</given-names></name>, <name><surname>Ledermann</surname><given-names>B</given-names></name>, <name><surname>Aguzzi</surname><given-names>A</given-names></name> (<year>2002</year>) <article-title>Absence of the prion protein homologue Doppel causes male sterility</article-title>. <source>EMBO J</source><volume>21</volume>: <fpage>1</fpage>&#x02013;<lpage>7</lpage><pub-id pub-id-type="pmid">11782420</pub-id></citation></ref><ref id="b3"><citation citation-type="journal"><name><surname>Beringue</surname><given-names>V</given-names></name>, <name><surname>Vilette</surname><given-names>D</given-names></name>, <name><surname>Mallinson</surname><given-names>G</given-names></name>, <name><surname>Archer</surname><given-names>F</given-names></name>, <name><surname>Kaisar</surname><given-names>M</given-names></name>, <name><surname>Tayebi</surname><given-names>M</given-names></name>, <name><surname>Jackson</surname><given-names>GS</given-names></name>, <name><surname>Clarke</surname><given-names>AR</given-names></name>, <name><surname>Laude</surname><given-names>H</given-names></name>, <name><surname>Collinge</surname><given-names>J</given-names></name>, <name><surname>Hawke</surname><given-names>S</given-names></name> (<year>2004</year>) <article-title>PrPSc binding antibodies are potent inhibitors of prion replication in cell lines</article-title>. <source>J Biol Chem</source><volume>279</volume>: <fpage>39671</fpage>&#x02013;<lpage>39676</lpage><pub-id pub-id-type="pmid">15133046</pub-id></citation></ref><ref id="b4"><citation citation-type="journal"><name><surname>Bounhar</surname><given-names>Y</given-names></name>, <name><surname>Zhang</surname><given-names>Y</given-names></name>, <name><surname>Goodyer</surname><given-names>CG</given-names></name>, <name><surname>LeBlanc</surname><given-names>A</given-names></name> (<year>2001</year>) <article-title>Prion protein protects human neurons against Bax-mediated apoptosis</article-title>. <source>J Biol Chem</source><volume>276</volume>: <fpage>39145</fpage>&#x02013;<lpage>39149</lpage><pub-id pub-id-type="pmid">11522774</pub-id></citation></ref><ref id="b5"><citation citation-type="journal"><name><surname>Brandner</surname><given-names>S</given-names></name>, <name><surname>Isenmann</surname><given-names>S</given-names></name>, <name><surname>Raeber</surname><given-names>A</given-names></name>, <name><surname>Fischer</surname><given-names>M</given-names></name>, <name><surname>Sailer</surname><given-names>A</given-names></name>, <name><surname>Kobayashi</surname><given-names>Y</given-names></name>, <name><surname>Marino</surname><given-names>S</given-names></name>, <name><surname>Weismann</surname><given-names>C</given-names></name>, <name><surname>Aguzzi</surname><given-names>A</given-names></name> (<year>1996</year>) <article-title>Normal host prion protein necessary for scrapie-induced neurotoxicity</article-title>. <source>Nature</source><volume>379</volume>: <fpage>339</fpage>&#x02013;<lpage>343</lpage><pub-id pub-id-type="pmid">8552188</pub-id></citation></ref><ref id="b6"><citation citation-type="journal"><name><surname>Brown</surname><given-names>D</given-names></name>, <name><surname>Belichenko</surname><given-names>P</given-names></name>, <name><surname>Sales</surname><given-names>J</given-names></name>, <name><surname>Jeffrey</surname><given-names>M</given-names></name>, <name><surname>Fraser</surname><given-names>JR</given-names></name> (<year>2001</year>) <article-title>Early loss of dendritic spines in murine scrapie revealed by confocal analysis</article-title>. <source>Neuroreport</source><volume>12</volume>: <fpage>179</fpage>&#x02013;<lpage>183</lpage><pub-id pub-id-type="pmid">11201083</pub-id></citation></ref><ref id="b7"><citation citation-type="journal"><name><surname>B&#x000fc;eler</surname><given-names>H</given-names></name>, <name><surname>Aguzzi</surname><given-names>A</given-names></name>, <name><surname>Sailer</surname><given-names>A</given-names></name>, <name><surname>Greiner</surname><given-names>R-A</given-names></name>, <name><surname>Autenried</surname><given-names>P</given-names></name>, <name><surname>Aguet</surname><given-names>M</given-names></name>, <name><surname>Weissmann</surname><given-names>C</given-names></name> (<year>1993</year>) <article-title>Mice devoid of PrP are resistant to scrapie</article-title>. <source>Cell</source><volume>73</volume>: <fpage>1339</fpage>&#x02013;<lpage>1347</lpage><pub-id pub-id-type="pmid">8100741</pub-id></citation></ref><ref id="b8"><citation citation-type="journal"><name><surname>B&#x000fc;eler</surname><given-names>H</given-names></name>, <name><surname>Fischer</surname><given-names>M</given-names></name>, <name><surname>Lang</surname><given-names>Y</given-names></name>, <name><surname>Bluethmann</surname><given-names>H</given-names></name>, <name><surname>Lipp</surname><given-names>HP</given-names></name>, <name><surname>DeArmond</surname><given-names>SJ</given-names></name>, <name><surname>Prusiner</surname><given-names>SB</given-names></name>, <name><surname>Aguet</surname><given-names>M</given-names></name>, <name><surname>Weissmann</surname><given-names>C</given-names></name> (<year>1992</year>) <article-title>Normal development and behaviour of mice lacking the neuronal cell-surface PrP protein</article-title>. <source>Nature</source><volume>356</volume>: <fpage>577</fpage>&#x02013;<lpage>582</lpage><pub-id pub-id-type="pmid">1373228</pub-id></citation></ref><ref id="b9"><citation citation-type="journal"><name><surname>Carlson</surname><given-names>GA</given-names></name>, <name><surname>Kingsbury</surname><given-names>DT</given-names></name>, <name><surname>Goodman</surname><given-names>PA</given-names></name>, <name><surname>Coleman</surname><given-names>S</given-names></name>, <name><surname>Marshall</surname><given-names>ST</given-names></name>, <name><surname>DeArmod</surname><given-names>SJ</given-names></name>, <name><surname>Westaway</surname><given-names>D</given-names></name>, <name><surname>Prusiner</surname><given-names>SB</given-names></name> (<year>1986</year>) <article-title>Linkage of prion protein and scrapie incubation time genes</article-title>. <source>Cell</source><volume>46</volume>: <fpage>503</fpage>&#x02013;<lpage>511</lpage><pub-id pub-id-type="pmid">3015416</pub-id></citation></ref><ref id="b10"><citation citation-type="journal"><name><surname>Chen</surname><given-names>SG</given-names></name>, <name><surname>Teplow</surname><given-names>D</given-names></name>, <name><surname>Parchi</surname><given-names>P</given-names></name>, <name><surname>Gambetti</surname><given-names>P</given-names></name>, <name><surname>Autilio-Gambetti</surname><given-names>L</given-names></name> (<year>1995</year>) <article-title>Truncated forms of the human prion protein in normal brain and in prion diseases</article-title>. <source>J Biol Chem</source><volume>270</volume>: <fpage>19173</fpage>&#x02013;<lpage>19180</lpage><pub-id pub-id-type="pmid">7642585</pub-id></citation></ref><ref id="b11"><citation citation-type="journal"><name><surname>Chiarini</surname><given-names>LB</given-names></name>, <name><surname>Freitas</surname><given-names>AR</given-names></name>, <name><surname>Zanata</surname><given-names>SM</given-names></name>, <name><surname>Brentani</surname><given-names>RR</given-names></name>, <name><surname>Martins</surname><given-names>VR</given-names></name>, <name><surname>Linden</surname><given-names>R</given-names></name> (<year>2002</year>) <article-title>Cellular prion protein transduces neuroprotective signals</article-title>. <source>EMBO J</source><volume>21</volume>: <fpage>3317</fpage>&#x02013;<lpage>3326</lpage><pub-id pub-id-type="pmid">12093733</pub-id></citation></ref><ref id="b12"><citation citation-type="journal"><name><surname>Chishti</surname><given-names>MA</given-names></name>, <name><surname>Yang</surname><given-names>DS</given-names></name>, <name><surname>Janus</surname><given-names>C</given-names></name>, <name><surname>Phinney</surname><given-names>AL</given-names></name>, <name><surname>Horne</surname><given-names>P</given-names></name>, <name><surname>Pearson</surname><given-names>J</given-names></name>, <name><surname>Strome</surname><given-names>R</given-names></name>, <name><surname>Zuker</surname><given-names>N</given-names></name>, <name><surname>Loukides</surname><given-names>J</given-names></name>, <name><surname>French</surname><given-names>J</given-names></name>, <name><surname>Turner</surname><given-names>S</given-names></name>, <name><surname>Lozza</surname><given-names>G</given-names></name>, <name><surname>Grilli</surname><given-names>M</given-names></name>, <name><surname>Kunicki</surname><given-names>S</given-names></name>, <name><surname>Morissette</surname><given-names>C</given-names></name>, <name><surname>Paquette</surname><given-names>J</given-names></name>, <name><surname>Gervais</surname><given-names>F</given-names></name>, <name><surname>Bergeron</surname><given-names>C</given-names></name>, <name><surname>Fraser</surname><given-names>PE</given-names></name>, <name><surname>Carlson</surname><given-names>GA</given-names></name><etal/> (<year>2001</year>) <article-title>Early-onset amyloid deposition and cognitive deficits in transgenic mice expressing a double mutant form of amyloid precursor protein 695</article-title>. <source>J Biol Chem</source><volume>276</volume>: <fpage>21562</fpage>&#x02013;<lpage>21570</lpage><pub-id pub-id-type="pmid">11279122</pub-id></citation></ref><ref id="b13"><citation citation-type="journal"><name><surname>Cui</surname><given-names>T</given-names></name>, <name><surname>Holme</surname><given-names>A</given-names></name>, <name><surname>Sassoon</surname><given-names>J</given-names></name>, <name><surname>Brown</surname><given-names>DR</given-names></name> (<year>2003</year>) <article-title>Analysis of doppel protein toxicity</article-title>. <source>Mol Cell Neurosci</source><volume>23</volume>: <fpage>144</fpage>&#x02013;<lpage>155</lpage><pub-id pub-id-type="pmid">12799144</pub-id></citation></ref><ref id="b14"><citation citation-type="journal"><name><surname>Donne</surname><given-names>D</given-names></name>, <name><surname>Viles</surname><given-names>JH</given-names></name>, <name><surname>Groth</surname><given-names>D</given-names></name>, <name><surname>Mehlhorn</surname><given-names>I</given-names></name>, <name><surname>James</surname><given-names>TL</given-names></name>, <name><surname>Cohen</surname><given-names>FE</given-names></name>, <name><surname>Prusiner</surname><given-names>SB</given-names></name>, <name><surname>Wright</surname><given-names>PE</given-names></name>, <name><surname>Dyson</surname><given-names>HJ</given-names></name> (<year>1997</year>) <article-title>Structure of the recombinant full-length hamster prion protein PrP(29&#x02013;231): the N terminus is highly flexible</article-title>. <source>Proc Natl Acad Sci USA</source><volume>94</volume>: <fpage>13452</fpage>&#x02013;<lpage>13457</lpage><pub-id pub-id-type="pmid">9391046</pub-id></citation></ref><ref id="b15"><citation citation-type="journal"><name><surname>Drisaldi</surname><given-names>B</given-names></name>, <name><surname>Coomaraswamy</surname><given-names>J</given-names></name>, <name><surname>Mastrangelo</surname><given-names>P</given-names></name>, <name><surname>Strome</surname><given-names>B</given-names></name>, <name><surname>Yang</surname><given-names>J</given-names></name>, <name><surname>Watts</surname><given-names>JC</given-names></name>, <name><surname>Chishti</surname><given-names>MA</given-names></name>, <name><surname>Marvi</surname><given-names>M</given-names></name>, <name><surname>Windl</surname><given-names>O</given-names></name>, <name><surname>Ahrens</surname><given-names>R</given-names></name>, <name><surname>Major</surname><given-names>F</given-names></name>, <name><surname>Sy</surname><given-names>MS</given-names></name>, <name><surname>Kretzschmar</surname><given-names>H</given-names></name>, <name><surname>Fraser</surname><given-names>PE</given-names></name>, <name><surname>Mount</surname><given-names>HT</given-names></name>, <name><surname>Westaway</surname><given-names>D</given-names></name> (<year>2004</year>) <article-title>Genetic mapping of activity determinants within cellular prion proteins: N-terminal modules in PrP<sup>C</sup> offset proapoptotic activity of the doppel helix B/B&#x02032; region</article-title>. <source>J Biol Chem</source><volume>279</volume>: <fpage>55443</fpage>&#x02013;<lpage>55454</lpage><pub-id pub-id-type="pmid">15459186</pub-id></citation></ref><ref id="b16"><citation citation-type="journal"><name><surname>Flechsig</surname><given-names>E</given-names></name>, <name><surname>Manson</surname><given-names>JC</given-names></name>, <name><surname>Barron</surname><given-names>R</given-names></name>, <name><surname>Aguzzi</surname><given-names>A</given-names></name>, <name><surname>Weissmann</surname><given-names>C</given-names></name> (<year>2004</year>) <article-title>Knockouts, knockins, transgenics and transplants in prion research</article-title>. In <source>Prion Biology and Diseases</source>, Prusiner SB (ed), pp <fpage>373</fpage>&#x02013;<lpage>434</lpage>. Cold Spring Harbor, NY: Cold Spring Harbor Press</citation></ref><ref id="b17"><citation citation-type="journal"><name><surname>Flechsig</surname><given-names>E</given-names></name>, <name><surname>Shmerling</surname><given-names>D</given-names></name>, <name><surname>Hegyi</surname><given-names>I</given-names></name>, <name><surname>Raeber</surname><given-names>AJ</given-names></name>, <name><surname>Fischer</surname><given-names>M</given-names></name>, <name><surname>Cozzio</surname><given-names>A</given-names></name>, <name><surname>von Mering</surname><given-names>C</given-names></name>, <name><surname>Aguzzi</surname><given-names>A</given-names></name>, <name><surname>Weissmann</surname><given-names>C</given-names></name> (<year>2000</year>) <article-title>Prion protein devoid of the octapeptide repeat region restores susceptibility to scrapie in PrP knockout mice</article-title>. <source>Neuron</source><volume>27</volume>: <fpage>399</fpage>&#x02013;<lpage>408</lpage><pub-id pub-id-type="pmid">10985358</pub-id></citation></ref><ref id="b18"><citation citation-type="journal"><name><surname>Hegde</surname><given-names>RS</given-names></name>, <name><surname>Tremblay</surname><given-names>P</given-names></name>, <name><surname>Groth</surname><given-names>D</given-names></name>, <name><surname>DeArmond</surname><given-names>SJ</given-names></name>, <name><surname>Prusiner</surname><given-names>SB</given-names></name>, <name><surname>Lingappa</surname><given-names>VR</given-names></name> (<year>1999</year>) <article-title>Transmissible and genetic prion diseases share a common pathway of neurodegeneration</article-title>. <source>Nature</source><volume>402</volume>: <fpage>822</fpage>&#x02013;<lpage>826</lpage><pub-id pub-id-type="pmid">10617204</pub-id></citation></ref><ref id="b19"><citation citation-type="journal"><name><surname>Hogan</surname><given-names>RN</given-names></name>, <name><surname>Baringer</surname><given-names>JR</given-names></name>, <name><surname>Prusiner</surname><given-names>SB</given-names></name> (<year>1987</year>) <article-title>Scrapie infection diminishes spines and increases varicosities of dendrites in hamsters: a quantitative Golgi analysis</article-title>. <source>J Neuropathol Exp Neurol</source><volume>46</volume>: <fpage>461</fpage>&#x02013;<lpage>473</lpage><pub-id pub-id-type="pmid">3598605</pub-id></citation></ref><ref id="b20"><citation citation-type="journal"><name><surname>Holscher</surname><given-names>C</given-names></name>, <name><surname>Delius</surname><given-names>H</given-names></name>, <name><surname>Burkle</surname><given-names>A</given-names></name> (<year>1998</year>) <article-title>Overexpression of nonconvertible PrP<sup>C</sup> delta114&#x02013;121 in scrapie-infected mouse neuroblastoma cells leads to trans-dominant inhibition of wild-type PrP(Sc) accumulation</article-title>. <source>J Virol</source><volume>72</volume>: <fpage>1153</fpage>&#x02013;<lpage>1159</lpage><pub-id pub-id-type="pmid">9445012</pub-id></citation></ref><ref id="b21"><citation citation-type="journal"><name><surname>Jeffrey</surname><given-names>M</given-names></name>, <name><surname>Goodsir</surname><given-names>CM</given-names></name>, <name><surname>Race</surname><given-names>RE</given-names></name>, <name><surname>Chesebro</surname><given-names>B</given-names></name> (<year>2004</year>) <article-title>Scrapie-specific neuronal lesions are independent of neuronal PrP expression</article-title>. <source>Ann Neurol</source><volume>55</volume>: <fpage>781</fpage>&#x02013;<lpage>792</lpage><pub-id pub-id-type="pmid">15174012</pub-id></citation></ref><ref id="b22"><citation citation-type="journal"><name><surname>Johnston</surname><given-names>AR</given-names></name>, <name><surname>Black</surname><given-names>C</given-names></name>, <name><surname>Fraser</surname><given-names>J</given-names></name>, <name><surname>MacLeod</surname><given-names>N</given-names></name> (<year>1997</year>) <article-title>Scrapie infection alters the membrane and synaptic properties of mouse hippocampal CA1 pyramidal neurones</article-title>. <source>J Physiol</source><volume>500</volume><issue>(Part 1)</issue>: <fpage>1</fpage>&#x02013;<lpage>15</lpage><pub-id pub-id-type="pmid">9097928</pub-id></citation></ref><ref id="b23"><citation citation-type="journal"><name><surname>Kimberlin</surname><given-names>RH</given-names></name>, <name><surname>Walker</surname><given-names>CA</given-names></name> (<year>1986</year>) <article-title>Pathogenesis of scrapie (strain 263K) in hamsters infected intracerebrally, intraperitoneally or intraocularly</article-title>. <source>J Gen Virol</source><volume>67</volume>: <fpage>255</fpage>&#x02013;<lpage>263</lpage><pub-id pub-id-type="pmid">3080549</pub-id></citation></ref><ref id="b24"><citation citation-type="journal"><name><surname>Kretzschmar</surname><given-names>HA</given-names></name>, <name><surname>Prusiner</surname><given-names>SB</given-names></name>, <name><surname>Stowring</surname><given-names>LE</given-names></name>, <name><surname>DeArmond</surname><given-names>SJ</given-names></name> (<year>1986</year>) <article-title>Scrapie prion proteins are synthesized in neurons</article-title>. <source>Am J Pathol</source><volume>122</volume>: <fpage>1</fpage>&#x02013;<lpage>5</lpage><pub-id pub-id-type="pmid">3079955</pub-id></citation></ref><ref id="b25"><citation citation-type="journal"><name><surname>Kuwahara</surname><given-names>C</given-names></name>, <name><surname>Takeuchi</surname><given-names>AM</given-names></name>, <name><surname>Nishimura</surname><given-names>T</given-names></name>, <name><surname>Haraguchi</surname><given-names>K</given-names></name>, <name><surname>Kubosaki</surname><given-names>A</given-names></name>, <name><surname>Matsumoto</surname><given-names>Y</given-names></name>, <name><surname>Saeki</surname><given-names>K</given-names></name>, <name><surname>Yokoyama</surname><given-names>T</given-names></name>, <name><surname>Itohara</surname><given-names>S</given-names></name>, <name><surname>Onodera</surname><given-names>T</given-names></name> (<year>1999</year>) <article-title>Prions prevent neuronal cell-line death</article-title>. <source>Nature</source><volume>400</volume>: <fpage>225</fpage>&#x02013;<lpage>226</lpage><pub-id pub-id-type="pmid">10421360</pub-id></citation></ref><ref id="b26"><citation citation-type="journal"><name><surname>Lee</surname><given-names>DC</given-names></name>, <name><surname>Sakudo</surname><given-names>A</given-names></name>, <name><surname>Kim</surname><given-names>CK</given-names></name>, <name><surname>Nishimura</surname><given-names>T</given-names></name>, <name><surname>Saeki</surname><given-names>K</given-names></name>, <name><surname>Matsumoto</surname><given-names>Y</given-names></name>, <name><surname>Yokoyama</surname><given-names>T</given-names></name>, <name><surname>Chen</surname><given-names>SG</given-names></name>, <name><surname>Itohara</surname><given-names>S</given-names></name>, <name><surname>Onodera</surname><given-names>T</given-names></name> (<year>2006</year>) <article-title>Fusion of Doppel to octapeptide repeat and N-terminal half of hydrophobic region of prion protein confers resistance to serum deprivation</article-title>. <source>Microbiol Immunol</source><volume>50</volume>: <fpage>203</fpage>&#x02013;<lpage>209</lpage><pub-id pub-id-type="pmid">16547418</pub-id></citation></ref><ref id="b27"><citation citation-type="journal"><name><surname>Li</surname><given-names>A</given-names></name>, <name><surname>Christensen</surname><given-names>HM</given-names></name>, <name><surname>Stewart</surname><given-names>LR</given-names></name>, <name><surname>Roth</surname><given-names>KA</given-names></name>, <name><surname>Chiesa</surname><given-names>R</given-names></name>, <name><surname>Harris</surname><given-names>DA</given-names></name> (<year>2007</year>) <article-title>Neonatal lethality in transgenic mice expressing prion protein with a deletion of residues 105&#x02013;125</article-title>. <source>EMBO J</source><volume>26</volume>: <fpage>548</fpage>&#x02013;<lpage>558</lpage><pub-id pub-id-type="pmid">17245437</pub-id></citation></ref><ref id="b28"><citation citation-type="journal"><name><surname>Li</surname><given-names>R</given-names></name>, <name><surname>Liu</surname><given-names>T</given-names></name>, <name><surname>Wong</surname><given-names>BS</given-names></name>, <name><surname>Pan</surname><given-names>T</given-names></name>, <name><surname>Morillas</surname><given-names>M</given-names></name>, <name><surname>Swietnicki</surname><given-names>W</given-names></name>, <name><surname>O'Rourke</surname><given-names>K</given-names></name>, <name><surname>Gambetti</surname><given-names>P</given-names></name>, <name><surname>Surewicz</surname><given-names>WK</given-names></name>, <name><surname>Sy</surname><given-names>MS</given-names></name> (<year>2000</year>) <article-title>Identification of an epitope in the C terminus of normal prion protein whose expression is modulated by binding events in the N terminus</article-title>. <source>J Mol Biol</source><volume>301</volume>: <fpage>567</fpage>&#x02013;<lpage>573</lpage><pub-id pub-id-type="pmid">10966770</pub-id></citation></ref><ref id="b29"><citation citation-type="journal"><name><surname>Liu</surname><given-names>T</given-names></name>, <name><surname>Zwingman</surname><given-names>T</given-names></name>, <name><surname>Li</surname><given-names>R</given-names></name>, <name><surname>Pan</surname><given-names>T</given-names></name>, <name><surname>Wong</surname><given-names>BS</given-names></name>, <name><surname>Petersen</surname><given-names>RB</given-names></name>, <name><surname>Gambetti</surname><given-names>P</given-names></name>, <name><surname>Herrup</surname><given-names>K</given-names></name>, <name><surname>Sy</surname><given-names>MS</given-names></name> (<year>2001</year>) <article-title>Differential expression of cellular prion protein in mouse brain as detected with multiple anti-PrP monoclonal antibodies</article-title>. <source>Brain Res</source><volume>896</volume>: <fpage>118</fpage>&#x02013;<lpage>129</lpage><pub-id pub-id-type="pmid">11277980</pub-id></citation></ref><ref id="b30"><citation citation-type="journal"><name><surname>Makrinou</surname><given-names>E</given-names></name>, <name><surname>Collinge</surname><given-names>J</given-names></name>, <name><surname>Antoniou</surname><given-names>M</given-names></name> (<year>2002</year>) <article-title>Genomic characterization of the human prion protein (PrP) gene locus</article-title>. <source>Mamm Genome</source><volume>13</volume>: <fpage>696</fpage>&#x02013;<lpage>703</lpage><pub-id pub-id-type="pmid">12514748</pub-id></citation></ref><ref id="b31"><citation citation-type="journal"><name><surname>McLennan</surname><given-names>NF</given-names></name>, <name><surname>Brennan</surname><given-names>PM</given-names></name>, <name><surname>McNeill</surname><given-names>A</given-names></name>, <name><surname>Davies</surname><given-names>I</given-names></name>, <name><surname>Fotheringham</surname><given-names>A</given-names></name>, <name><surname>Rennison</surname><given-names>KA</given-names></name>, <name><surname>Ritchie</surname><given-names>D</given-names></name>, <name><surname>Brannan</surname><given-names>F</given-names></name>, <name><surname>Head</surname><given-names>MW</given-names></name>, <name><surname>Ironside</surname><given-names>JW</given-names></name>, <name><surname>Williams</surname><given-names>A</given-names></name>, <name><surname>Bell</surname><given-names>JE</given-names></name> (<year>2004</year>) <article-title>Prion protein accumulation and neuroprotection in hypoxic brain damage</article-title>. <source>Am J Pathol</source><volume>165</volume>: <fpage>227</fpage>&#x02013;<lpage>235</lpage><pub-id pub-id-type="pmid">15215178</pub-id></citation></ref><ref id="b32"><citation citation-type="journal"><name><surname>Miesbauer</surname><given-names>M</given-names></name>, <name><surname>Bamme</surname><given-names>T</given-names></name>, <name><surname>Riemer</surname><given-names>C</given-names></name>, <name><surname>Oidtmann</surname><given-names>B</given-names></name>, <name><surname>Winklhofer</surname><given-names>KF</given-names></name>, <name><surname>Baier</surname><given-names>M</given-names></name>, <name><surname>Tatzelt</surname><given-names>J</given-names></name> (<year>2006</year>) <article-title>Prion protein-related proteins from zebrafish are complex glycosylated and contain a glycosylphosphatidylinositol anchor</article-title>. <source>Biochem Biophys Res Commun</source><volume>341</volume>: <fpage>218</fpage>&#x02013;<lpage>224</lpage><pub-id pub-id-type="pmid">16414019</pub-id></citation></ref><ref id="b33"><citation citation-type="journal"><name><surname>Mo</surname><given-names>H</given-names></name>, <name><surname>Moore</surname><given-names>RC</given-names></name>, <name><surname>Cohen</surname><given-names>FE</given-names></name>, <name><surname>Westaway</surname><given-names>D</given-names></name>, <name><surname>Prusiner</surname><given-names>SB</given-names></name>, <name><surname>Wright</surname><given-names>PE</given-names></name>, <name><surname>Dyson</surname><given-names>HJ</given-names></name> (<year>2001</year>) <article-title>Two different neurodegenerative diseases caused by proteins with similar structures</article-title>. <source>Proc Natl Acad Sci USA</source><volume>98</volume>: <fpage>2352</fpage>&#x02013;<lpage>2357</lpage><pub-id pub-id-type="pmid">11226243</pub-id></citation></ref><ref id="b34"><citation citation-type="journal"><name><surname>Moore</surname><given-names>R</given-names></name>, <name><surname>Mastrangelo</surname><given-names>P</given-names></name>, <name><surname>Bouzamondo</surname><given-names>E</given-names></name>, <name><surname>Heinrich</surname><given-names>C</given-names></name>, <name><surname>Legname</surname><given-names>G</given-names></name>, <name><surname>Prusiner</surname><given-names>SB</given-names></name>, <name><surname>Hood</surname><given-names>L</given-names></name>, <name><surname>Westaway</surname><given-names>D</given-names></name>, <name><surname>DeArmond</surname><given-names>S</given-names></name>, <name><surname>Tremblay</surname><given-names>P</given-names></name> (<year>2001</year>) <article-title>Doppel-induced cerebellar degeneration in transgenic mice</article-title>. <source>Proc Natl Acad Sci USA</source><volume>98</volume>: <fpage>15288</fpage>&#x02013;<lpage>15293</lpage><pub-id pub-id-type="pmid">11734625</pub-id></citation></ref><ref id="b35"><citation citation-type="journal"><name><surname>Nishida</surname><given-names>N</given-names></name>, <name><surname>Tremblay</surname><given-names>P</given-names></name>, <name><surname>Sugimoto</surname><given-names>T</given-names></name>, <name><surname>Shigematsu</surname><given-names>K</given-names></name>, <name><surname>Shirabe</surname><given-names>S</given-names></name>, <name><surname>Petromilli</surname><given-names>C</given-names></name>, <name><surname>Pilkuhn</surname><given-names>S</given-names></name>, <name><surname>Nakaoke</surname><given-names>R</given-names></name>, <name><surname>Atarashi</surname><given-names>R</given-names></name>, <name><surname>Houtani</surname><given-names>T</given-names></name>, <name><surname>Torchia</surname><given-names>M</given-names></name>, <name><surname>Sakaguchi</surname><given-names>S</given-names></name>, <name><surname>DeArmond</surname><given-names>SJ</given-names></name>, <name><surname>Prusiner</surname><given-names>SB</given-names></name>, <name><surname>Katamine</surname><given-names>S</given-names></name> (<year>1999</year>) <article-title>Degeneration of Purkinje cells and demyelination in the spinal cord and peripheral nerves of mice lacking the prion protein gene (<italic>Prnp</italic>) is rescued by introduction of a transgene encoded for mouse <italic>Prnp</italic></article-title>. <source>Lab Invest</source><volume>79</volume>: <fpage>689</fpage>&#x02013;<lpage>697</lpage><pub-id pub-id-type="pmid">10378511</pub-id></citation></ref><ref id="b36"><citation citation-type="journal"><name><surname>Novitskaya</surname><given-names>V</given-names></name>, <name><surname>Bocharova</surname><given-names>OV</given-names></name>, <name><surname>Bronstein</surname><given-names>I</given-names></name>, <name><surname>Baskakov</surname><given-names>IV</given-names></name> (<year>2006</year>) <article-title>Amyloid fibrils of mammalian prion protein are highly toxic to cultured cells and primary neurons</article-title>. <source>J Biol Chem</source><volume>281</volume>: <fpage>13828</fpage>&#x02013;<lpage>13836</lpage><pub-id pub-id-type="pmid">16554307</pub-id></citation></ref><ref id="b37"><citation citation-type="journal"><name><surname>Paisley</surname><given-names>D</given-names></name>, <name><surname>Banks</surname><given-names>S</given-names></name>, <name><surname>Selfridge</surname><given-names>J</given-names></name>, <name><surname>McLennan</surname><given-names>NF</given-names></name>, <name><surname>Ritchie</surname><given-names>AM</given-names></name>, <name><surname>McEwan</surname><given-names>C</given-names></name>, <name><surname>Irvine</surname><given-names>DS</given-names></name>, <name><surname>Saunders</surname><given-names>PT</given-names></name>, <name><surname>Manson</surname><given-names>JC</given-names></name>, <name><surname>Melton</surname><given-names>DW</given-names></name> (<year>2004</year>) <article-title>Male infertility and DNA damage in Doppel knockout and prion protein/Doppel double-knockout mice</article-title>. <source>Am J Pathol</source><volume>164</volume>: <fpage>2279</fpage>&#x02013;<lpage>2288</lpage><pub-id pub-id-type="pmid">15161660</pub-id></citation></ref><ref id="b38"><citation citation-type="journal"><name><surname>Pan</surname><given-names>KM</given-names></name>, <name><surname>Stahl</surname><given-names>N</given-names></name>, <name><surname>Prusiner</surname><given-names>SB</given-names></name> (<year>1992</year>) <article-title>Purification and properties of the cellular prion protein from Syrian hamster brain</article-title>. <source>Protein Sci</source><volume>1</volume>: <fpage>1343</fpage>&#x02013;<lpage>1352</lpage><pub-id pub-id-type="pmid">1363897</pub-id></citation></ref><ref id="b39"><citation citation-type="journal"><name><surname>Parkin</surname><given-names>ET</given-names></name>, <name><surname>Watt</surname><given-names>NT</given-names></name>, <name><surname>Turner</surname><given-names>AJ</given-names></name>, <name><surname>Hooper</surname><given-names>NM</given-names></name> (<year>2004</year>) <article-title>Dual mechanisms for shedding of the cellular prion protein</article-title>. <source>J Biol Chem</source><volume>279</volume>: <fpage>11170</fpage>&#x02013;<lpage>11178</lpage><pub-id pub-id-type="pmid">14711812</pub-id></citation></ref><ref id="b40"><citation citation-type="journal"><name><surname>Peretz</surname><given-names>D</given-names></name>, <name><surname>Williamson</surname><given-names>RA</given-names></name>, <name><surname>Kaneko</surname><given-names>K</given-names></name>, <name><surname>Vergara</surname><given-names>J</given-names></name>, <name><surname>Leclerc</surname><given-names>E</given-names></name>, <name><surname>Schmitt-Ulms</surname><given-names>G</given-names></name>, <name><surname>Mehlhorn</surname><given-names>IR</given-names></name>, <name><surname>Legname</surname><given-names>G</given-names></name>, <name><surname>Wormald</surname><given-names>MR</given-names></name>, <name><surname>Rudd</surname><given-names>PM</given-names></name>, <name><surname>Dwek</surname><given-names>RA</given-names></name>, <name><surname>Burton</surname><given-names>DR</given-names></name>, <name><surname>Prusiner</surname><given-names>SB</given-names></name> (<year>2001</year>) <article-title>Antibodies inhibit prion propagation and clear cell cultures of prion infectivity</article-title>. <source>Nature</source><volume>412</volume>: <fpage>739</fpage>&#x02013;<lpage>743</lpage><pub-id pub-id-type="pmid">11507642</pub-id></citation></ref><ref id="b41"><citation citation-type="journal"><name><surname>Peretz</surname><given-names>D</given-names></name>, <name><surname>Williamson</surname><given-names>RA</given-names></name>, <name><surname>Matsunaga</surname><given-names>Y</given-names></name>, <name><surname>Serban</surname><given-names>H</given-names></name>, <name><surname>Pinilla</surname><given-names>C</given-names></name>, <name><surname>Bastidas</surname><given-names>RB</given-names></name>, <name><surname>Rozenshteyn</surname><given-names>R</given-names></name>, <name><surname>James</surname><given-names>TL</given-names></name>, <name><surname>Houghten</surname><given-names>RA</given-names></name>, <name><surname>Cohen</surname><given-names>FE</given-names></name>, <name><surname>Prusiber</surname><given-names>SB</given-names></name>, <name><surname>Burton</surname><given-names>DR</given-names></name> (<year>1997</year>) <article-title>A conformational transition at the N terminus of the prion protein features in formation of the scrapie isoform</article-title>. <source>J Mol Biol</source><volume>273</volume>: <fpage>614</fpage>&#x02013;<lpage>622</lpage><pub-id pub-id-type="pmid">9356250</pub-id></citation></ref><ref id="b42"><citation citation-type="journal"><name><surname>Peterson</surname><given-names>KE</given-names></name>, <name><surname>Errett</surname><given-names>JS</given-names></name>, <name><surname>Wei</surname><given-names>T</given-names></name>, <name><surname>Dimcheff</surname><given-names>DE</given-names></name>, <name><surname>Ransohoff</surname><given-names>R</given-names></name>, <name><surname>Kuziel</surname><given-names>WA</given-names></name>, <name><surname>Evans</surname><given-names>L</given-names></name>, <name><surname>Chesebro</surname><given-names>B</given-names></name> (<year>2004</year>) <article-title>MCP-1 and CCR2 contribute to non-lymphocyte-mediated brain disease induced by Fr98 polytropic retrovirus infection in mice: role for astrocytes in retroviral neuropathogenesis</article-title>. <source>J Virol</source><volume>78</volume>: <fpage>6449</fpage>&#x02013;<lpage>6458</lpage><pub-id pub-id-type="pmid">15163738</pub-id></citation></ref><ref id="b43"><citation citation-type="journal"><name><surname>Premzl</surname><given-names>M</given-names></name>, <name><surname>Gready</surname><given-names>JE</given-names></name>, <name><surname>Jermiin</surname><given-names>LS</given-names></name>, <name><surname>Simonic</surname><given-names>T</given-names></name>, <name><surname>Marshall Graves</surname><given-names>JA</given-names></name> (<year>2004</year>) <article-title>Evolution of vertebrate genes related to prion and Shadoo proteins&#x02014;clues from comparative genomic analysis</article-title>. <source>Mol Biol Evol</source><volume>21</volume>: <fpage>2210</fpage>&#x02013;<lpage>2231</lpage><pub-id pub-id-type="pmid">15342797</pub-id></citation></ref><ref id="b44"><citation citation-type="journal"><name><surname>Premzl</surname><given-names>M</given-names></name>, <name><surname>Sangiorgio</surname><given-names>L</given-names></name>, <name><surname>Strumbo</surname><given-names>B</given-names></name>, <name><surname>Marshall Graves</surname><given-names>JA</given-names></name>, <name><surname>Simonic</surname><given-names>T</given-names></name>, <name><surname>Gready</surname><given-names>JE</given-names></name> (<year>2003</year>) <article-title>Shadoo, a new protein highly conserved from fish to mammals and with similarity to prion protein</article-title>. <source>Gene</source><volume>314</volume>: <fpage>89</fpage>&#x02013;<lpage>102</lpage><pub-id pub-id-type="pmid">14527721</pub-id></citation></ref><ref id="b45"><citation citation-type="journal"><name><surname>Prusiner</surname><given-names>SB</given-names></name>, <name><surname>Scott</surname><given-names>M</given-names></name>, <name><surname>Foster</surname><given-names>D</given-names></name>, <name><surname>Pan</surname><given-names>K-M</given-names></name>, <name><surname>Groth</surname><given-names>D</given-names></name>, <name><surname>Mirenda</surname><given-names>C</given-names></name>, <name><surname>Torchia</surname><given-names>M</given-names></name>, <name><surname>Yang</surname><given-names>S-L</given-names></name>, <name><surname>Serban</surname><given-names>D</given-names></name>, <name><surname>Carlson</surname><given-names>GA</given-names></name>, <name><surname>Hoppe</surname><given-names>PC</given-names></name>, <name><surname>Westaway</surname><given-names>D</given-names></name>, <name><surname>DeArmond</surname><given-names>SJ</given-names></name> (<year>1990</year>) <article-title>Transgenetic studies implicate interactions between homologous PrP isoforms in scrapie prion replication</article-title>. <source>Cell</source><volume>63</volume>: <fpage>673</fpage>&#x02013;<lpage>686</lpage><pub-id pub-id-type="pmid">1977523</pub-id></citation></ref><ref id="b46"><citation citation-type="journal"><name><surname>Riek</surname><given-names>R</given-names></name>, <name><surname>Hornemann</surname><given-names>S</given-names></name>, <name><surname>Wider</surname><given-names>G</given-names></name>, <name><surname>Billeter</surname><given-names>M</given-names></name>, <name><surname>Glockshuber</surname><given-names>R</given-names></name>, <name><surname>Wuthrich</surname><given-names>K</given-names></name> (<year>1996</year>) <article-title>NMR structure of the mouse prion protein domain PrP (121&#x02013;231)</article-title>. <source>Nature</source><volume>382</volume>: <fpage>180</fpage>&#x02013;<lpage>183</lpage><pub-id pub-id-type="pmid">8700211</pub-id></citation></ref><ref id="b47"><citation citation-type="journal"><name><surname>Riek</surname><given-names>R</given-names></name>, <name><surname>Hornemann</surname><given-names>S</given-names></name>, <name><surname>Wider</surname><given-names>G</given-names></name>, <name><surname>Glockshuber</surname><given-names>R</given-names></name>, <name><surname>Wuthrich</surname><given-names>K</given-names></name> (<year>1997</year>) <article-title>NMR characterization of the full-length recombinant murine prion protein, <italic>m</italic>PrP(23&#x02013;231)</article-title>. <source>FEBS Lett</source><volume>413</volume>: <fpage>282</fpage>&#x02013;<lpage>288</lpage><pub-id pub-id-type="pmid">9280298</pub-id></citation></ref><ref id="b48"><citation citation-type="journal"><name><surname>Rossi</surname><given-names>D</given-names></name>, <name><surname>Cozzio</surname><given-names>A</given-names></name>, <name><surname>Flechsig</surname><given-names>E</given-names></name>, <name><surname>Klein</surname><given-names>MA</given-names></name>, <name><surname>Rulicke</surname><given-names>T</given-names></name>, <name><surname>Aguzzi</surname><given-names>A</given-names></name>, <name><surname>Weissmann</surname><given-names>C</given-names></name> (<year>2001</year>) <article-title>Onset of ataxia and Purkinje cell loss in PrP null mice inversely correlated with Dpl level in brain</article-title>. <source>EMBO J</source><volume>20</volume>: <fpage>694</fpage>&#x02013;<lpage>702</lpage><pub-id pub-id-type="pmid">11179214</pub-id></citation></ref><ref id="b49"><citation citation-type="journal"><name><surname>Sakudo</surname><given-names>A</given-names></name>, <name><surname>Lee</surname><given-names>DC</given-names></name>, <name><surname>Nakamura</surname><given-names>I</given-names></name>, <name><surname>Taniuchi</surname><given-names>Y</given-names></name>, <name><surname>Saeki</surname><given-names>K</given-names></name>, <name><surname>Matsumoto</surname><given-names>Y</given-names></name>, <name><surname>Itohara</surname><given-names>S</given-names></name>, <name><surname>Ikuta</surname><given-names>K</given-names></name>, <name><surname>Onodera</surname><given-names>T</given-names></name> (<year>2005</year>) <article-title>Cell-autonomous PrP&#x02013;Doppel interaction regulates apoptosis in PrP gene-deficient neuronal cells</article-title>. <source>Biochem Biophys Res Commun</source><volume>333</volume>: <fpage>448</fpage>&#x02013;<lpage>454</lpage><pub-id pub-id-type="pmid">15950943</pub-id></citation></ref><ref id="b50"><citation citation-type="journal"><name><surname>Scott</surname><given-names>M</given-names></name>, <name><surname>Foster</surname><given-names>D</given-names></name>, <name><surname>Mirenda</surname><given-names>C</given-names></name>, <name><surname>Serban</surname><given-names>D</given-names></name>, <name><surname>Coufal</surname><given-names>F</given-names></name>, <name><surname>W&#x000e4;lchli</surname><given-names>M</given-names></name>, <name><surname>Torchia</surname><given-names>M</given-names></name>, <name><surname>Groth</surname><given-names>D</given-names></name>, <name><surname>Carlson</surname><given-names>G</given-names></name>, <name><surname>DeArmond</surname><given-names>SJ</given-names></name>, <name><surname>Westaway</surname><given-names>D</given-names></name>, <name><surname>Prusiner</surname><given-names>SB</given-names></name> (<year>1989</year>) <article-title>Transgenic mice expressing hamster prion protein produce species-specific scrapie infectivity and amyloid plaques</article-title>. <source>Cell</source><volume>59</volume>: <fpage>847</fpage>&#x02013;<lpage>857</lpage><pub-id pub-id-type="pmid">2574076</pub-id></citation></ref><ref id="b51"><citation citation-type="journal"><name><surname>Shmerling</surname><given-names>D</given-names></name>, <name><surname>Hegyi</surname><given-names>I</given-names></name>, <name><surname>Fischer</surname><given-names>M</given-names></name>, <name><surname>Blattler</surname><given-names>T</given-names></name>, <name><surname>Brandner</surname><given-names>S</given-names></name>, <name><surname>G&#x000f6;tz</surname><given-names>J</given-names></name>, <name><surname>Rulicke</surname><given-names>T</given-names></name>, <name><surname>Flechsig</surname><given-names>E</given-names></name>, <name><surname>Cozzio</surname><given-names>A</given-names></name>, <name><surname>von Meering</surname><given-names>C</given-names></name>, <name><surname>Hangartner</surname><given-names>C</given-names></name>, <name><surname>Aguzzi</surname><given-names>A</given-names></name>, <name><surname>Weissmann</surname><given-names>C</given-names></name> (<year>1998</year>) <article-title>Expression of amino-terminally truncated PrP in the mouse leading to ataxia and specific cerebellar lesions</article-title>. <source>Cell</source><volume>93</volume>: <fpage>203</fpage>&#x02013;<lpage>214</lpage><pub-id pub-id-type="pmid">9568713</pub-id></citation></ref><ref id="b52"><citation citation-type="journal"><name><surname>Shyu</surname><given-names>WC</given-names></name>, <name><surname>Lin</surname><given-names>SZ</given-names></name>, <name><surname>Chiang</surname><given-names>MF</given-names></name>, <name><surname>Ding</surname><given-names>DC</given-names></name>, <name><surname>Li</surname><given-names>KW</given-names></name>, <name><surname>Chen</surname><given-names>SF</given-names></name>, <name><surname>Yang</surname><given-names>HI</given-names></name>, <name><surname>Li</surname><given-names>H</given-names></name> (<year>2005</year>) <article-title>Overexpression of PrP<sup>C</sup> by adenovirus-mediated gene targeting reduces ischemic injury in a stroke rat model</article-title>. <source>J Neurosci</source><volume>25</volume>: <fpage>8967</fpage>&#x02013;<lpage>8977</lpage><pub-id pub-id-type="pmid">16192387</pub-id></citation></ref><ref id="b53"><citation citation-type="journal"><name><surname>Silverman</surname><given-names>GL</given-names></name>, <name><surname>Qin</surname><given-names>K</given-names></name>, <name><surname>Moore</surname><given-names>RC</given-names></name>, <name><surname>Yang</surname><given-names>Y</given-names></name>, <name><surname>Mastrangelo</surname><given-names>P</given-names></name>, <name><surname>Tremblay</surname><given-names>P</given-names></name>, <name><surname>Prusiner</surname><given-names>SB</given-names></name>, <name><surname>Cohen</surname><given-names>FE</given-names></name>, <name><surname>Westaway</surname><given-names>D</given-names></name> (<year>2000</year>) <article-title>Doppel is an <italic>N</italic>-glycosylated, glycosylphosphatidylinositol-anchored protein: expression in testis and ectopic production in the brains of Prnp0/0 mice predisposed to Purkinje cell loss</article-title>. <source>J Biol Chem</source><volume>275</volume>: <fpage>26834</fpage>&#x02013;<lpage>26841</lpage><pub-id pub-id-type="pmid">10842180</pub-id></citation></ref><ref id="b54"><citation citation-type="journal"><name><surname>Solforosi</surname><given-names>L</given-names></name>, <name><surname>Criado</surname><given-names>JR</given-names></name>, <name><surname>McGavern</surname><given-names>DB</given-names></name>, <name><surname>Wirz</surname><given-names>S</given-names></name>, <name><surname>Sanchez-Alavez</surname><given-names>M</given-names></name>, <name><surname>Sugama</surname><given-names>S</given-names></name>, <name><surname>DeGiorgio</surname><given-names>LA</given-names></name>, <name><surname>Volpe</surname><given-names>BT</given-names></name>, <name><surname>Wiseman</surname><given-names>E</given-names></name>, <name><surname>Abalos</surname><given-names>G</given-names></name>, <name><surname>Masliah</surname><given-names>E</given-names></name>, <name><surname>Gilden</surname><given-names>D</given-names></name>, <name><surname>Oldstone</surname><given-names>MB</given-names></name>, <name><surname>Conti</surname><given-names>B</given-names></name>, <name><surname>Williamson</surname><given-names>RA</given-names></name> (<year>2004</year>) <article-title>Crosslinking cellular prion protein triggers neuronal apoptosis <italic>in vivo</italic></article-title>. <source>Science</source><volume>303</volume>: <fpage>1514</fpage>&#x02013;<lpage>1516</lpage><pub-id pub-id-type="pmid">14752167</pub-id></citation></ref><ref id="b55"><citation citation-type="journal"><name><surname>Spudich</surname><given-names>A</given-names></name>, <name><surname>Frigg</surname><given-names>R</given-names></name>, <name><surname>Kilic</surname><given-names>E</given-names></name>, <name><surname>Kilic</surname><given-names>U</given-names></name>, <name><surname>Oesch</surname><given-names>B</given-names></name>, <name><surname>Raeber</surname><given-names>A</given-names></name>, <name><surname>Bassetti</surname><given-names>CL</given-names></name>, <name><surname>Hermann</surname><given-names>DM</given-names></name> (<year>2005</year>) <article-title>Aggravation of ischemic brain injury by prion protein deficiency: role of ERK-1/-2 and STAT-1</article-title>. <source>Neurobiol Dis</source><volume>20</volume>: <fpage>442</fpage>&#x02013;<lpage>449</lpage><pub-id pub-id-type="pmid">15893468</pub-id></citation></ref><ref id="b56"><citation citation-type="journal"><name><surname>Sunyach</surname><given-names>C</given-names></name>, <name><surname>Jen</surname><given-names>A</given-names></name>, <name><surname>Deng</surname><given-names>J</given-names></name>, <name><surname>Fitzgerald</surname><given-names>KT</given-names></name>, <name><surname>Frobert</surname><given-names>Y</given-names></name>, <name><surname>Grassi</surname><given-names>J</given-names></name>, <name><surname>McCaffrey</surname><given-names>MW</given-names></name>, <name><surname>Morris</surname><given-names>R</given-names></name> (<year>2003</year>) <article-title>The mechanism of internalization of glycosylphosphatidylinositol-anchored prion protein</article-title>. <source>EMBO J</source><volume>22</volume>: <fpage>3591</fpage>&#x02013;<lpage>3601</lpage><pub-id pub-id-type="pmid">12853474</pub-id></citation></ref><ref id="b57"><citation citation-type="journal"><name><surname>Taraboulos</surname><given-names>A</given-names></name>, <name><surname>Jendroska</surname><given-names>K</given-names></name>, <name><surname>Serban</surname><given-names>D</given-names></name>, <name><surname>Yang</surname><given-names>S-L</given-names></name>, <name><surname>DeArmond</surname><given-names>SJ</given-names></name>, <name><surname>Prusiner</surname><given-names>SB</given-names></name> (<year>1992</year>) <article-title>Regional mapping of prion proteins in brains</article-title>. <source>Proc Natl Acad Sci USA</source><volume>89</volume>: <fpage>7620</fpage>&#x02013;<lpage>7624</lpage><pub-id pub-id-type="pmid">1354357</pub-id></citation></ref><ref id="b58"><citation citation-type="journal"><name><surname>Vincent</surname><given-names>B</given-names></name>, <name><surname>Paitel</surname><given-names>E</given-names></name>, <name><surname>Frobert</surname><given-names>Y</given-names></name>, <name><surname>Lehmann</surname><given-names>S</given-names></name>, <name><surname>Grassi</surname><given-names>J</given-names></name>, <name><surname>Checler</surname><given-names>F</given-names></name> (<year>2000</year>) <article-title>Phorbol ester-regulated cleavage of normal prion protein in HEK293 human cells and murine neurons</article-title>. <source>J Biol Chem</source><volume>275</volume>: <fpage>35612</fpage>&#x02013;<lpage>35616</lpage><pub-id pub-id-type="pmid">10952979</pub-id></citation></ref><ref id="b59"><citation citation-type="journal"><name><surname>Weise</surname><given-names>J</given-names></name>, <name><surname>Crome</surname><given-names>O</given-names></name>, <name><surname>Sandau</surname><given-names>R</given-names></name>, <name><surname>Schulz-Schaeffer</surname><given-names>W</given-names></name>, <name><surname>Bahr</surname><given-names>M</given-names></name>, <name><surname>Zerr</surname><given-names>I</given-names></name> (<year>2004</year>) <article-title>Upregulation of cellular prion protein (PrP<sup>C</sup>) after focal cerebral ischemia and influence of lesion severity</article-title>. <source>Neurosci Lett</source><volume>372</volume>: <fpage>146</fpage>&#x02013;<lpage>150</lpage><pub-id pub-id-type="pmid">15531106</pub-id></citation></ref><ref id="b60"><citation citation-type="journal"><name><surname>Wopfner</surname><given-names>F</given-names></name>, <name><surname>Weidenhofer</surname><given-names>G</given-names></name>, <name><surname>Schneider</surname><given-names>R</given-names></name>, <name><surname>von Brunn</surname><given-names>A</given-names></name>, <name><surname>Gilch</surname><given-names>S</given-names></name>, <name><surname>Schwarz</surname><given-names>TF</given-names></name>, <name><surname>Werner</surname><given-names>T</given-names></name>, <name><surname>Schatzl</surname><given-names>HM</given-names></name> (<year>1999</year>) <article-title>Analysis of 27 mammalian and 9 avian PrPs reveals high conservation of flexible regions of the prion protein</article-title>. <source>J Mol Biol</source><volume>289</volume>: <fpage>1163</fpage>&#x02013;<lpage>1178</lpage><pub-id pub-id-type="pmid">10373359</pub-id></citation></ref></ref-list></back><floats-wrap><fig id="f1"><label>Figure 1</label><caption><p>Domain structure of Dpl, PrP&#x00394;32&#x02013;121, PrP and Sho. &#x003b1;-Helices (A, B and C) are boxed. A basic repeat region in Sho is stippled and the hydrophobic domain in PrP and Sho is striped. Neuroprotective &#x02018;determinants', sequences required for PrP's neuroprotective action and mapped genetically, are shown in boxed numbers, and an expanded view shows the central hydrophobic regions of PrP and Sho aligned with the T-COFFEE algorithm. PrP and Sho deletions used in this study are bracketed alongside the alignment. Two residues that correspond to the N-termini of human PrP &#x02018;C1' fragment are underlined. &#x02018;Neurotoxic' and &#x02018;neuroprotective' refer to assays in cerebellar granule cell cultures or Tg mice (see main text).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="7601830f1"/></fig><fig id="f2"><label>Figure 2</label><caption><p>Analysis of recombinant Sho in <italic>E. coli</italic> and expression of murine Sho in cultured cells. (<bold>A</bold>) Schematic representation of the Sho protein. The location of the mapped epitopes for &#x003b1;-Sho peptide antisera (04SH-1 and 06SH-3) and &#x003b1;-recombinant Sho (06rSH-1) are shown. (<bold>B</bold>) Circular dichroism spectrum of recombinant mouse Sho, rSho(25&#x02013;122). The spectral trace is consistent with a random coil configuration. (<bold>C</bold>) Cell surface expression of wt Sho and a mutant Sho allele lacking the hydrophobic tract in non-permeabilized transfected N2a cells as demonstrated by immunocytochemistry. Scale bar, 50 microns. (<bold>D</bold>) Diminution of Sho signal in the cell lysates of Sho-transfected N2a cells following pretreatment with increasing concentrations of PI-PLC. (<bold>E</bold>) Western blot showing expression of a wt Sho transgene in N2a cells with or without PNGaseF treatment. A lysate from cells transfected with empty vector is included to show antibody specificity.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="7601830f2"/></fig><fig id="f3"><label>Figure 3</label><caption><p>Analysis of mouse Sho in tissue preparations. (<bold>A</bold>) Expression of Sho in whole mouse embryos assessed by Western blotting using a 12&#x00025; Tris&#x02013;glycine gel. Sho is expressed beginning at embryonic day 16. (<bold>B</bold>) Postnatal expression of Sho in neonatal and adult mouse brains with or without PNGaseF treatment assessed by Western blotting using 14&#x00025; Tris&#x02013;glycine (&#x003b1;-rSho) or 4&#x02013;12&#x00025; NuPAGE (&#x003b1;-Sho(86&#x02013;100) peptide and &#x003b1;-PrP) gels. Full-length species before and after enzymatic treatment are bracketed. (<bold>C</bold>) Sho is present in a membrane-enriched fraction prepared from mouse brains. Membrane preparations with or without PNGaseF treatment were analyzed on 4&#x02013;12&#x00025; NuPAGE gels by Western blotting. Sho was detected using either &#x003b1;-Sho peptide polyclonal 04SH-1 (A&#x02013;C) or &#x003b1;-recombinant Sho polyclonal 06rSH-1 (B), whereas PrP was probed with single-chain antibodies D13 (A&#x02013;B) or D18 (C).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="7601830f3"/></fig><fig id="f4ah"><label>Figure 4ah</label><caption><p>Localization of <italic>Sprn</italic> mRNA and Sho protein in the adult mouse brain. (<bold>A&#x02013;H</bold>) The hippocampus, and (<bold>I&#x02013;P</bold>) the cerebellum. wt C57/B6 mice are presented in all sections, with the exception of B6 congenic <italic>Prnp</italic><sup>0/0</sup> (E, M) and Tg(SHaPrP)7 mice (H, P). Panels A, C, E, G, I, K, M and O in the left-hand columns comprise negative controls (i.e., sense-strand riboprobes, peptide-directed antisera preincubated with a soluble form of the antigenic peptide, <italic>Prnp</italic><sup>0/0</sup> mice for PrP-directed antibodies) for analyses presented in the right-hand columns. <italic>In situ</italic> hybridization: panels A, B, and I, J represent hybridizations with Sho sense-strand (A, I) or antisense (B, J) cRNA probe. Sections are not counterstained and blue staining from NBT/BCIP substrate represents hybridization to <italic>Sprn</italic> mRNA. Immunohistochemistry: all other panels of mouse brains with genotypes as noted above. Anti-Sho antibody 04SH-1 (&#x003b1;-Sho) antibody was used with (C, K) or without (D, L) preincubation with Sho(86&#x02013;100) peptide. Antibodies 7A12 and 3F4 were used for the detection of mouse PrP (E, F, M, N) and hamster PrP (G, H, O, P), respectively. Note the Sho staining of CA1 apical dendritic processes (D, black bracket) and Purkinje cell layer (L, white arrow), and absence of Purkinje cell-body staining with &#x003b1;-moPrP (N) and relative paucity of staining with &#x003b1;-HaPrP antibody (P, black arrow). Scale bar in panels A&#x02013;H, and I&#x02013;P, 100 &#x003bc;m.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="7601830f4ah"/></fig><fig id="f4ip"><label>Figure 4ip</label><caption><p>Continued.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="7601830f4ip"/></fig><fig id="f5"><label>Figure 5</label><caption><p>Reciprocal and overlapping expression of Sho and PrP<sup>C</sup> in the CNS. (<bold>A&#x02013;E</bold>) CA1 hippocampal neurons of adult mice probed as indicated. The signal for Sho immunohistochemistry in apical dendrites of wt mice (A&#x02013;C) has an equivalent in a &#x02018;negative image' (white brackets) in the molecular layer of the neuropil imaged for either mouse PrP (D) or hamster PrP in Tg(SHaPrP)7 mice (E). Apical dendrites were less intensely stained with the &#x003b1;-Sho 06rSH-1 antibody (C, black arrowhead) Analogous analyses are presented for Purkinje cells (<bold>F&#x02013;J</bold>). Somatodendritic localization of Sho in Purkinje cell bodies and dendritic arborizations (F&#x02013;H) is contrasted by a reciprocal &#x02018;negative image' in molecular layer of the neuropil imaged for either mouse PrP (I) or hamster PrP in Tg(SHaPrP)7 mice (J). Note the complete absence of MoPrP staining in cell bodies (I, black arrowheads). Somatodendritic localization of calbindin in Purkinje cells of wt mice (<bold>K</bold>) is shown for comparative purposes. (<bold>L&#x02013;N</bold>) The cerebral cortex probed simultaneously with &#x003b1;-Sho (06rSH-1, green) and &#x003b1;-PrP (8H4, red) antibodies. Overlapping PrP<sup>C</sup> and Sho expression is observed in neurons of the cerebral cortex, including colocalization in cell bodies (N, white arrowheads). Scale bar, 25 &#x003bc;m (A&#x02013;E), 10 &#x003bc;m (F&#x02013;K) or 20 &#x003bc;m (L&#x02013;N).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="7601830f5"/></fig><fig id="f6"><label>Figure 6</label><caption><p>Neuroprotective activity and Sho expression in CGN cells. Test for toxicity of PrP mutant alleles versus the performance of neurotoxic wtDpl and PrP&#x00394;32&#x02013;121 controls in single transfections (<bold>A</bold>), results of cotransfections of PrP deletion mutants, wt Sho and pBUD.GFP empty vector controls with wtDpl plasmid (<bold>B</bold>), and results of cotransfections to assess putative protective effects of Sho and internally deleted Sho versus a toxic PrP&#x00394;32&#x02013;121 allele (<bold>C</bold>). Determinations (&#x00025; cells&#x000b1;s.e.m undergoing apoptosis) reflect the results of two or more triplicate transfections of independent batches of <italic>Prnp</italic><sup>0/0</sup> CGNs scored by independent observers. Whereas PrP&#x00394;100&#x02013;105 and wt Sho had potent neuroprotective activity (both <italic>P</italic>&#x0003c;0.001, <italic>n</italic>&#x0003d;6, <italic>n</italic>&#x0003d;11, respectively) not significantly different from that of wt PrP, PrP&#x00394;91&#x02013;99 and PrP&#x00394;106&#x02013;112 exhibited a tendency for reduced neuroprotective activity against Dpl (neither cotransfection is significantly different than Dpl single transfections). Sho&#x00394;62&#x02013;77 cotransfections were not significantly different from Dpl or PrP&#x00394;32&#x02013;121 single transfections. PrP&#x00394;106&#x02013;121 (<italic>n</italic>&#x0003d;11) transfected alone was significantly different from wt PrP (<italic>P</italic>&#x0003c;0.01; <italic>n</italic>&#x0003d;15) and all other PrP alleles (<italic>P</italic>&#x0003c;0.001), with the exception of the previously documented toxic PrP&#x00394;32&#x02013;121 allele (<xref ref-type="bibr" rid="b51">Shmerling <italic>et al</italic>, 1998</xref>): PrP&#x00394;32&#x02013;121 (<italic>n</italic>&#x0003d;7) versus wt PrP, <italic>P</italic>&#x0003c;0.001. Cerebellar granule cell assays for bioactivity, creation of plasmid constructs and verification of protein expression were performed as described previously (<xref ref-type="bibr" rid="b15">Drisaldi <italic>et al</italic>, 2004</xref>; <xref ref-type="supplementary-material" rid="S1">Supplementary Figure 3</xref>) <sup>&#x0002a;&#x0002a;</sup><italic>P</italic>&#x0003c;0.01, <sup>&#x0002a;&#x0002a;&#x0002a;</sup><italic>P</italic>&#x0003c;0.001. (<bold>D</bold>) Western blot analysis using 06rSH-1 detects Sho in mouse brain lysates but not in a normalized loading of lysate derived from mouse CGNs. &#x02018;ns'&#x0003d;non-specific bands detected by the antibody. (<bold>E</bold>) Immunocytochemistry on non-permeabilized CGNs cotransfected with non-fluorescent Sho and PrP&#x00394;32&#x02013;121 plasmids (3:1 ratio). Sho was detected with 06rSH-1 and PrP&#x00394;32&#x02013;121 with 8H4. Both Sho and PrP&#x00394;32&#x02013;121 are expressed in a single cell and colocalization is observed in the cell body. Scale bar, 15 &#x003bc;m.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="7601830f6"/></fig><fig id="f7"><label>Figure 7</label><caption><p>Reduced Sho levels in clinically ill prion-infected mice. (<bold>A</bold>) Western blot of homogenates prepared from the brains of non-inoculated or clinically ill (average of 172 days post-inoculation) RML prion-inoculated mice (C3H/C57BL6 background). Sho protein levels are notably reduced in prion-infected brains. Levels of the GPI-anchored protein Thy-1 are shown for comparison purposes. (<bold>B</bold>) Quantitation of Sho (06rSH-1) and Thy-1 blot signals in panel A by densitometry. Sho levels in prion-infected brains (normalized against Thy-1 signal) are reduced to 12.1&#x000b1;2.8&#x00025; (<italic>P</italic>&#x0003c;0.001) the levels observed in non-inoculated mice. <sup>&#x0002a;&#x0002a;&#x0002a;</sup><italic>P</italic>&#x0003c;0.001. (<bold>C</bold>) Expression of neuronal markers in prion-infected and control mouse brains as assessed by Western blotting. No change in neuron-specific enolase (NSE) or calbindin levels, and only a moderate decrease in synaptophysin levels are observed in prion-infected brains. (<bold>D</bold>) No change in Sho levels are observed in brain homogenates prepared from clinically ill (8 months old) Tg mice (TgCRND8) expressing a familial Alzheimer's disease-associated variant of the amyloid precursor protein and control non-Tg littermates. (<bold>E</bold>) Reduced Sho expression in normalized brain homogenates in a second cohort of RML-inoculated mice versus control mice injected with a brain homogenate from healthy mice (C57BL6 background, 154 days post inoculation).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="7601830f7"/></fig></floats-wrap></article> 